

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

## Unraveling the link between periodontitis and abdominal aortic calcification in the U.S. adult population: A crosssectional study based on the NHANES 2013-2014

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-068931
Article Type:	Original research
Date Submitted by the Author:	06-Oct-2022
Complete List of Authors:	Kadier, Kaisaierjiang; Xinjiang Medical University Affiliated First Hospital, Cardiology Abulizi, Anniwaer; Xinjiang Medical University Affiliated First Hospital Ainiwaer, Aikeliyaer; Xinjiang Medical University Affiliated First Hospital Rehemuding, Rena; Xinjiang Medical University Affiliated First Hospital, Department of Cardiology Ma, Xiang; Xinjiang Medical University Affiliated First Hospital, Heart Center Ma, Yi-Tong ; Xinjiang Medical University Affiliated First Hospital
Keywords:	Vascular medicine < INTERNAL MEDICINE, PUBLIC HEALTH, ORAL MEDICINE, EPIDEMIOLOGY, Cardiac Epidemiology < CARDIOLOGY
	·





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

R. O.

BMJ Open: first published as 10.1136/bmjopen-2022-068931 on 15 March 2023. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright.

1 2 3 4 5	1	The title page
6 7 8 9	2	Unraveling the link between periodontitis and abdominal aortic
9 10 11 12	3	calcification in the U.S. adult population: A cross-sectional study based
13 14 15	4	on the NHANES 2013-2014
16 17 18	5	Kaisaierjiang Kadier*, Anniwaer Abulizi*, Aikeliyaer Ainiwaer*, Rena Rehemuding, Xiang
19 20 21	6	Ma, and Yi-Tong Ma
22 23 24	7	Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
25 26 27 28	8	Correspondence:
29 30	9	Xiang Ma, Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University,
31 32 33	10	Xinyi Road No. 393, Urumqi 830054, China. Email: maxiangxj@yeah.net
34 35 36	11	Yi-Tong Ma, Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University,
37 38 39	12	Xinyi Road No. 393, Urumqi 830054, China. Email: myt_xj@sina.com
40 41 42	13	Equal contributions: *These authors have contributed equally to this work and share first authorship
43 44 45 46	14	Word count: 3,603; Number of figures: 1; Number of tables: 4; Number of references: 48.
47 48 49 50	15	Abstract
50 51 52	16	Objective: We aimed to explore the association between periodontitis and abdominal aortic
53 54 55	17	calcification (AAC) among a nationally representative sample of U.S. adults.
56 57 58	18	Design: Cross- sectional study.
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 1

#### **BMJ** Open

Setting: The National Health and Nutrition Examination Survey (2013–2014). Participants: A total of 2,149 participants aged 40 years or older who have complete information for periodontitis and AAC assessment test were included in this study. Primary and secondary outcome measures: AAC scores can be accurately identified on lateral spine images obtained by DXA, and both the AAC-24 and AAC-8 semiguantitative scoring tools were used for AAC evaluation. Linear regression analysis was used to investigate the relationship between periodontitis and the AAC-8 and AAC-24 scores. Multivariate logistic regression models and reported odds ratios (ORs) were used to examine the relationship between periodontitis and AAC. **Results:** The prevalence of severe periodontitis combined with severe AAC was 8.49%-8.54%. According to the AAC-8 and AAC-24 score classifications, patients with severe periodontitis had higher odds of severe AAC [AAC-8 score  $\geq$  3: (OR: 2.53; 95% CI 1.04, 6.17) and AAC-24 score >6: (OR: 3.60; 95% CI 1.48, 8.78)]. A positive association between mild-moderate periodontitis and severe AAC was found only when the AAC-24 score was applied (OR: 2.25; 95% CI 1.24, 4.06). In the subgroup analyses, the likelihood ratio test showed no multiplicative interaction (all P for interaction > 0.05). Conclusions: The findings showed that periodontitis is associated with an increased risk of severe 

AAC in the U.S. population aged 40 years and older; this requires further large-scale prospective studies for confirmation.

<sup>48</sup><sub>49</sub> 37 Strengths and limitations of this study

1. This is the first population-based cross-sectional epidemiological study to explore the link between
periodontitis and AAC in a nationally representative sample of U.S. adults (40 years and older).

#### 

40 2. Our study fully considered socioeconomic status, behavioral factors and medical history of the41 participants and controlled for a wide range of confounders.

2 3. Given the cross-sectional design of the NHANES, it is difficult for us to determine causality, and

43 further large-scale prospective studies are needed

4 4. Because of the sample size, we were not able to include the new periodontal profile class (PPC)
5 system to precisely classify periodontal disease

## Text

### 1. Introduction

Periodontitis has become a global public health challenge and imposes serious burdens on society and health services. There have been approximately 1.1 billion prevalent cases of severe periodontitis worldwide over the past 30 years, an increase of 8.44% in age-standardized prevalence<sup>1</sup>. Forty-six percent of American adults aged 30 years and older have periodontitis, 8.9% of whom have severe periodontitis, which is positively associated with increasing age<sup>2</sup>. Periodontitis can affect the risk of systemic diseases, including cardiovascular disease (CVD)<sup>3-4</sup>, diabetes<sup>5</sup>, and chronic kidney disease (CKD)<sup>6</sup>, through mechanisms such as periodontal microbial damage and inflammatory cascades, and this relationship may be causal and bidirectional. Deaths due to all causes and cause-specific causes are associated with periodontitis and its sequelae<sup>7</sup>. As part of its strategy, the Centers for Disease Control and Prevention (CDC) is supporting and improving periodontal disease surveillance<sup>8</sup>.

The abdominal aorta is considered to valuable in observing early atherosclerotic calcification<sup>9</sup>, and its degree of calcification is closely related to the prevalence of and mortality due to CVD<sup>10</sup>. Abdominal aortic calcification (AAC) is characterized by metabolic disorders involving minerals, such as calcium and phosphorus, and abnormal deposition in the vascular wall, which is common in patients

#### BMJ Open

with chronic disease<sup>11-12</sup>. Some epidemiological evidence suggests that periodontitis is associated with arterial calcification at multiple sites. A Chinese cohort study showed that periodontitis increased the risk of aortic calcification and was more pronounced in men and younger participants than in women and older participants<sup>13</sup>. In addition, a cross-sectional study and meta-analysis suggested that periodontitis was associated with carotid calcification<sup>14-15</sup>, and there was radiographic evidence suggesting the possible involvement of intracranial carotid calcification<sup>16</sup>. However, other cohort studies reported inconsistent conclusions<sup>17-18</sup>. In recent years, vascular calcification, including soft tissue calcification, has been recognized as an active process regulated by multiple molecular signaling pathways in response to chronic inflammatory stimuli<sup>19</sup>. Previous animal studies demonstrated that periodontitis and vascular calcification promoted each other<sup>20</sup>, and the mechanisms involved were gradually revealed in subsequent studies<sup>21-24</sup>. 

An assessment of the utility of the AAC score in a 25-year cohort study of 617 Framingham Heart Study participants was conducted by Kauppila et al. using lateral lumbar radiography as the AAC grading tool (AAC score)<sup>25</sup>. Based on the AAC score, it is possible to assess subclinical vascular disease at a low cost, with predictive value for cardiovascular events and mortality independent of coronary calcification<sup>26</sup>. Therefore, using abdominal aortic calcification data obtained from dual-energy X-ray absorptiometry (DXA) in the 2013–2014 National Health and Nutrition Examination Survey (NHANES), the aim of this study was to investigate the relationship between periodontitis and AAC and propose new ideas for the prevention and management of AAC in clinical practice. We hypothesized that periodontitis would be associated with an increased prevalence of AAC.

- 82 2. Materials and methods
- **2.1. Data source**

84 The current cross-sectional study analyzed data from individuals who participated in the 2013 to
 85 2014 NHANES, which was performed by the National Center for Health Statistics (NCHS) at the CDC.
 86 2014 NHANES, which was performed by the National Center for Health Statistics (NCHS) at the CDC.

BMJ Open: first published as 10.1136/bmjopen-2022-068931 on 15 March 2023. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright.

BMJ Open: first published as 10.1136/bmjopen-2022-068931 on 15 March 2023. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright

86 The NHANES 2013-2014 was a cross-sectional, nationally representative survey of the U.S. 87 noninstitutionalized civilian population designed to examine demographic, socioeconomic, health, and 88 nutritional information. To ensure a representative sample, complex multistage sampling was used to 89 collect data, and strata were determined based on geographic location and population proportions<sup>27</sup>.

The NHANES 2013-2014 was the only cycle that also performed examinations for periodontitis and abdominal aortic calcification. Participants  $\geq 40$  years of age who received a full-mouth periodontal examination and participated in lateral DXA scans of the thoraco-lumbar spine were included in this study. In the 2013-2014 cycle of the NHANES, 10,175 participants completed the survey. However, in this study, individuals aged < 40 years without complete information about periodontitis and abdominal aortic calcification were excluded (N = 7,741). Additionally, cancer participants (N = 285) were excluded from the analysis. Ultimately, 2,149 participants were included in the analysis (Figure 1). All participants provided written informed consent to participate in NHANES, and the NCHS Research Ethics Review Board approved the protocol (NCHS IRB/ERB Protocol Number: Continuation of Protocol #2011-17). The study was designed according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for reporting cross-sectional studies<sup>28</sup>, and all procedures were performed in accordance with the principles of the Helsinki Declaration of 1975.

## **2.2. Definitions of periodontitis**

Oral health examinations were performed by dental examiners who were licensed dentists in at least one state in the U.S. During oral health assessments, a portable dental chair, lights, and compressed air were provided in a mobile examination center (MEC). All dental examiners received standardized training and collected reliable statistical data to objectively assess examiner agreement<sup>29</sup>. Page 7 of 34

#### **BMJ** Open

Six measurement points were selected for periodontal examinations (mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual) for all teeth, with the exception of third molars. Indicators of periodontitis included probing depth (PD) and clinical attachment loss (AL), which are important bases for the CDC/AAP classification/case definition<sup>30</sup>. Accordingly, periodontitis was divided into mild periodontitis, moderate periodontitis and severe periodontitis, No periodontitis was defined as no evidence of mild, moderate, or severe periodontitis. Because there were few data from those with mild periodontitis, mild periodontitis and moderate periodontitis were combined for analysis in our study. 2.3. Abdominal aortic calcification outcomes AAC can be accurately identified on lateral spine images obtained by DXA and shows good sensitivity and specificity at lower radiation doses<sup>31-32</sup>. Those < 40 years old, pregnant, weighing over 450 pounds, or ingesting barium within the last week were ineligible for DXA scans in this study. Both the AAC-24 and AAC-8 semiguantitative scoring tools were used for AAC evaluation<sup>25</sup>. An assessment of the length of anterior and posterior aortic wall calcification anterior to the L1 to L4 vertebral bodies was made using the AAC-8 score, and participants with a score of three or more were considered to be at high risk for AAC. Using the L1-L4 region as a reference, the anterior and posterior aortic walls are divided into four segments to calculate the AAC-24 score. Depending on the degree of calcification, each vertebral body can receive a score from 0 to 6, with a total possible score of 0 to 24; this allows a more precise assessment of abdominal aortic calcification. We categorized AAC-24 scores into three groups: no calcification (AAC-24 score =0), mild to moderate calcification ( $6 \ge AAC-24$ score > 0) and severe calcification (AAC-24 score > 6). 2.4. Covariates 

BMJ Open: first published as 10.1136/bmjopen-2022-068931 on 15 March 2023. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright

Based on previous studies, we considered some confounding factors potentially associated with periodontitis and AAC in our analysis, including socioeconomic factors, behavioral factors, body mass index (BMI), medical history, and laboratory measurements<sup>33-34</sup>.

Information about socioeconomic factors was obtained during the home interview. The poverty income ratio (PIR) was stratified into <1.3, 1.3-3.5, and >3.5, as recorded in the original survey. Behavioral factors were obtained from self-reports. A never smoker is an individual who has never smoked more than 100 cigarettes in their lifetime. Former smokers were defined as those who smoked more than 100 cigarettes in their lifetime and had guit smoking, and smokers have to smoke at least 100 cigarettes in their lifetime and smoke some days or every day to qualify as current smokers. The status of alcohol consumption was categorised as never (never drank greater than or equal to 12 drinks in their lifetime), former (greater than or equal to 12 drinks in 1 year and did not drink last year, or did not drink last year but drank  $\geq 12$  drinks in their lifetime), current mild ( $\leq 1$  drink/d for female or  $\leq 2 \operatorname{drink/d}$  for male on average over the past year), current moderate (2 drink/d for female or 3 drink/d for male on average over the past year), current heavy drinkers ( $\geq$ 3 drink/d for female or  $\geq$ 4 drink/d for male on average over the past year). BMI was measured at a MEC using standard protocols and stratified into  $\geq$ 30 and <30.

Those participants who self-reported heart failure, angina, coronary heart disease, heart attack, or stroke diagnosed by a physician were classified as having CVD. The definition of hypertension was a diagnosis by a healthcare professional, an average blood pressure of  $\geq$  130/80 mmHg or using hypertension medications<sup>35</sup>. Diabetes was defined as a diagnosis made by a physician or other healthcare professional, HbA1c (%) >6.5, random blood glucose (mmol/l)  $\geq$ 11.1, or use of diabetes medication or insulin. As defined by the International Renal Association, chronic kidney disease is characterized by an estimated glomerular filtration rate <60 mL/min/1.73 m<sup>2</sup> or a urine Page 9 of 34

#### **BMJ** Open

albumin–creatinine ratio of at least 30<sup>36</sup>. Based on serum creatinine, the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation was used to estimate the glomerular filtration rate<sup>37</sup>.
Laboratory data were obtained from participant serum samples that were processed in the Collaborative
Laboratory Services, Ottumwa, Iowa, for analysis. Detailed instructions regarding specimen collection
and processing are documented in the NHANES Laboratory Procedures Manual, and quality control
was in accordance with standard procedures.

**2.5. Statistical analysis** 

A weight is assigned to the NHANES to compensate for the complex survey design, survey nonresponses, and poststratification adjustment to match the total U.S. population.. All results of this study were weighted by 2-year MEC weights. In accordance with the CDC/AAP classification of periodontitis, descriptive statistics were calculated to describe the characteristics of the participants. Continuous variables are presented as the weighted mean  $\pm$  standard deviation (SD) and were compared using a one-way ANOVA, while categorical variables were compared using the Rao-Scott chi-square test and are presented as weighted percentages (95% confidence interval, 95% CI). Linear regression was used to evaluate the association of the AAC-8 score and AAC-24 score as dependent variables with periodontitis with varying degrees of severity as independent variables. Beta coefficients and 95% CIs were calculated. Multivariate logistic regression analysis was performed to evaluate the correlation between periodontitis with varying degrees of severity and AAC with varying degrees of severity using odds ratios (ORs) and 95% CIs. Model 1 was adjusted for age, sex, and race; Model 2 was adjusted for the parameters in Model 1 plus insurance, education level, smoking status, alcohol consumption status, PIR, BMI, diabetes, hypertension, CVD and CKD; and Model 3 was adjusted for the parameters in Model 2 plus albumin, serum calcium, serum phosphorus, uric acid, total 25-hydroxyvitamin D, hemoglobin, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TGs). Subgroup analysis stratified by age, sex, CVD, hypertension, diabetes, and CKD was also 

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

conducted using stratified multivariate regression analysis, and multiplicative interactions were assessed using likelihood ratio tests.

In this study, we used the MissForest<sup>38</sup> package in R software to address missing covariates. The algorithm can address categorical and continuous variables and shows superior performance. The numbers and percentages of missing covariate data are shown in Supplementary Material Table 1. Sensitivity analyses were performed as followed: (1) only participants with complete data were included, and participants with missing covariates were excluded; (2) mild and moderate periodontitis were not combined for analysis, and mild periodontitis was excluded; and (3) participants with CVD were excluded. R software (version 4.1.3) was used for all statistical analyses. It was considered statistically significant if the P value was less than 0.05 for all statistical tests of two-tailed.

2.6. Patient and public involvement

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

Descriptive statistics of our study participants by periodontitis status according to the CDC/AAP case definitions are presented in Table 1. The study included 2,149 participants, representing 86,199,511 noninstitutionalized adults (40 years and older) in the U.S. Overall, participants had a mean age $\pm$ SD of 54.96  $\pm$  0.32 years; 50.46% (44.32, 56.60) were female, and 68.14% (54.20, 82.08) were non-Hispanic white. The prevalence of mild-moderate periodontitis was 29.93 (25.36, 34.51) and that of severe periodontitis was 6.77 (5.40, 8.13). Periodontitis was more prevalent in older individuals, males, those with a low educational level, those with a low PIR, and those with low insurance coverage than in their counterparts and showed differences among races. The prevalence of mild to moderate AAC and severe AAC was significantly higher in participants with periodontitis than in those without. In addition, we also found significant differences in smoking status, alcohol consumption status, CVD, 

2 3 4

5 6

59

60

#### BMJ Open

201	diabetes, hypertension,	CKD, albumin, tota	al 25-hydroxyvitamin D,	, TGs, a	and HDL-C compared with
-----	-------------------------	--------------------	-------------------------	----------	-------------------------

202 participants without periodontitis (all p < 0.05).

 $\begin{array}{c} 7 \\ 8 \\ 9 \end{array} \begin{array}{c} 203 \\ 204 \end{array} \quad \mbox{TABLE 1 General characteristics of included participants (n = 2,149) according to the periodontal status in the NHANES 2013-2014. \end{array}$ 

Characters	Overall (n=2,149)	No Periodontitis (n=1,142)	Mild-Moderate periodontitisc (n=787)	Severe periodontitis (n=220)	P-value
Age, year	54.96±0.32	$53.84 \pm 0.47$	$57.13 \pm 0.52$	$55.78 \pm 0.73$	0.001
Gender					< 0.001
Male	49.54 (42.66-56.42)	44.26 (40.95-47.57)	56.17 (52.43-59.91)	69.60 (62.25-76.96)	
Female	50.46 (44.32,56.60)	55.74 (52.43-59.05)	43.83 (40.09-47.57)	30.40 (23.04-37.75)	
Race		· · · · · ·	· · · · · ·	· · · · · ·	< 0.001
Mexican American	7.98 (4.63-11.32)	5.51 (2.88-8.15)	12.60 (6.75-18.46)	10.53 (4.02-17.05)	
Non-Hispanic Black		7.38 (5.67-9.09)	14.16 (9.15-19.17)	23.88 (15.54-32.23)	
Non-Hispanic White		74.71 (69.73-79.70)	57.60 (46.77-68.43)	53.28 (42.62-63.94)	
Other Hispanic	5.22 ( 3.48- 6.95)	4.38 (2.56-6.20)	6.79 (4.13-9.44)	6.09 (2.77-9.41)	
Other race or multi-r		8.02 (6.44-9.60)	8.85 (6.07-11.63)	6.21 (4.11-8.31)	
Education					< 0.001
Less than hight scho	ol 14.88 (12.36-17.39)	9.09 ( 6.59-11.59)	22.21 (17.08-27.35)	36.60 (27.56-45.64)	
Hight school	20.80 (17.18-24.43)	16.38 (13.54-19.21)	27.28 (22.81-31.75)	33.56 (26.94-40.19)	
Above hight school	64.32 (52.71-75.93)	74.54 (70.84-78.23)	50.51 (44.66-56.35)	29.84 (20.31-39.37)	
Poverty-income rat			( (	(	< 0.001
< 1.3	16.84 (12.82-20.86)	10.14 (7.11-13.16)	27.38 (21.64-33.13)	32.91 (20.83-44.99)	
1.3-3.5	34.58 (30.67-38.50)	29.18 (25.57-32.80)	43.20 (38.79-47.62)	46.98 (36.21-57.75)	
> 3.5	48.58 (38.30-58.85)	60.68 (55.49-65.87)	29.41 (23.79-35.03)	20.11 (10.19-30.04)	
Insurance coverage		91.46 (88.41-94.50)	76.37 (72.89-79.85)	62.68 (55.51-69.85)	< 0.001
Body mass index (k		91.10 (00.11 9 1.00)	10.51 (12.05 15.00)	02.00 (00.01 0).00)	0.053
< 30	64.10 (54.77-73.44)	66.54 (63.36-69.72)	59.50 (53.18-65.82)	61.67 (53.95-69.39)	0.055
$\geq 30$	35.90 (31.24-40.56)	33.46 (30.28-36.64)	40.50 (34.18-46.82)	38.33 (30.61-46.05)	
Smoking status	55.70 (51.24-40.50)	33.40 (30.20-30.04)	40.30 (34.10-40.02)	50.55 (50.01-40.05)	< 0.001
Now	16.07 (13.82-18.31)	10.48 ( 8.12-12.83)	21.91 (18.01-25.81)	42.48 (33.91-51.05)	< 0.001
Former	25.38 (20.70-30.06)	23.00 (20.09-25.92)	31.13 (25.05-37.20)	22.22 (13.02-31.43)	
Never	58.55 (50.16-66.94)	66.52 (62.55-70.48)	46.96 (42.06-51.87)	35.30 (25.73-44.86)	
Alcohol consumption		00.52 (02.55-70.48)	40.90 (42.00-31.87)	55.50 (25.75-44.80)	0.004
Never	11.48 ( 8.45-14.51)	11.22 (7.14-15.29)	12.77 (10.23-15.30)	8.23 ( 4.19-12.27)	0.004
Former	14.23 (11.41-17.06)	11.54 (9.13-13.95)	18.94 (15.82-22.05)	18.63 (12.99-24.26)	
Mild	· · · · · · · · · · · · · · · · · · ·			( )	
Moderate	40.28 (33.73-46.83)	43.77 (39.36-48.18)	34.64 (29.89-39.39)	32.56 (24.85-40.26)	
	18.10 (14.08-22.11)	18.98 (16.05-21.92)	16.60 (11.73-21.47)	16.44 (9.60-23.28)	
Heavy	15.91 (13.83-18.00)	14.49 (12.30-16.68)	17.06 (13.06-21.06)	24.15 (16.68-31.61)	0.004
Cardiovascular dise		5.95 (4.53-7.38)	10.68 (7.93-13.43)	6.88 (3.11-10.65)	0.004 < 0.001
Hypertension	56.64 (50.33-62.94)	52.31 (48.43-56.19)	63.24 (59.08-67.39)	67.92 (61.80-74.05)	
Diabetes	14.06 (12.22-15.91)	10.83 (8.78-12.87)	21.13 (18.83-23.43)	13.04 (7.94-18.15)	< 0.001
Chronic kidney dis	ease 14.66 (12.77-16.55)	12.21 (10.24-14.19)	19.73 (17.14-22.31)	15.13 (10.15-20.11)	< 0.001
AAC-8 score	04.06 (02.16.100.00)	0( (0 (05 02 00 12)	01 70 (00 21 04 05)	01 51 (0( 0( 0( 70)	0.001
< 3	94.86 (83.16-100.00)	96.68 (95.23-98.13)	91.78 (89.31-94.25)	91.51 (86.26-96.76)	
$\geq$ 3	5.14 ( 3.60-6.68)	3.32 (1.87-4.77)	8.22 (5.75-10.69)	8.49 (3.24-13.74)	. 0. 001
AAC-24 score					< 0.001
0	75.67 (64.85-86.49)	77.77 (74.00-81.53)	73.24(67.18-79.30)	66.81(59.03-74.58)	
1-6	19.55 (15.84-23.26)	19.38 (15.83-22.93)	18.75(14.07-23.43)	24.65(17.37-31.93)	
> 6	4.78 ( 3.66-5.90)	2.85 (1.95-3.76)	8.01(5.59-10.42)	8.54(4.04-13.04)	
Laboratory measur					
Albumin (g/dL)	$4.27 \pm 0.01$	$4.30 \pm 0.01$	$4.21 \pm 0.02$	$4.20 \pm 0.02$	< 0.001
Serum calcium (mg/		$9.45 \pm 0.01$	$9.43 \pm 0.02$	$9.45 \pm 0.03$	0.414
Serum phosphorus (1	mg/dL) 3.79±0.02	$3.81 \pm 0.03$	$3.75 \pm 0.02$	$3.78 \pm 0.04$	0.083
Uric acid (mg/dL)	5.37±0.03	$5.29 \pm 0.03$	$5.53 \pm 0.08$	$5.42 \pm 0.13$	0.063
Total 25-hydroxyvita	min D				
(nmol/L)	$73.44 \pm 1.18$	$76.90 \pm 1.44$	$68.78 \pm 1.58$	$61.71 \pm 2.42$	< 0.001
Hemoglobin (g/dL)	$14.19 \pm 0.04$	$14.15 \pm 0.04$	$14.20 \pm 0.08$	$14.42 \pm 0.11$	0.097
memogloom (g/dL)	1 1.17 - 0.07	11.12 - 0.04	11.20 - 0.00	1 1. 12 - 0.11	0.071

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2							
3		Total cholesterol (mg/dL)	196.56±0.99	195.79±1.15	197.98±2.45	197.48±3.31	0.722
4		High-density lipoprotein cholesterol (mg/dL)	$54.67 \pm 0.60$	$56.42 \pm 0.73$	51.79±0.70	$50.99 \pm 1.19$	< 0.001
5 6		Triglycerides (mg/dL)	$162.83 \pm 3.69$	152.54± 3.39	$182.64 \pm 9.60$	171.49±13.54	0.015
7	205	Note: Values indicate the we					
8 9 10	206	AAC, abdominal aortic calci	fication.				-
11 12 13	207	Table 2 shows the re	lationships betw	veen periodontitis a	and the AAC-8 sco	re and AAC-24	score in
14 15 16	208	the linear regression an	alysis. In Mod	el 1, which was	adjusted for age,	sex, and race	e, severe
17 18	209	periodontitis showed a si	gnificant positi	ve correlation with	the AAC-8 ( $\beta$ : 0.	29; 95% CI 0.0	08, 0.50)
19 20	210	and AAC-24 ( $\beta$ : 0.80;	95% CI 0.25, 1	1.34) scores compa	ared with no perio	odontitis. Howe	ever, the
21 22 23	211	association disappeared i	n the subseque	nt models adjusted	for additional cov	variates. In add	ition, no
24 25	212	correlation was found bet	ween mild-mod	lerate periodontitis	and the AAC-8 sc	ore or AAC-24	score.
26 27	213	TABLE 2 Weighted line	ar regression coe	fficients (B) and 95%	o confidence intervals	for periodontal	status and
28 29 30	214	AAC score : The United Stat	2			I	
31 32							
33			Case/participants	Model 1 β (95% CI), P- value	Model 2 β (95% CI), P- valu	Model e β (95% CI),	
		AAC-8 score		β (95% CI), P- value	β (95% CI), P- valu	e $\beta$ (95% CI),	P- value
33 34 35 36		No periodontitis	1142/2149				P- value
33 34 35 36 37			1142/2149 787/2149	β (95% CI), P- value Reference 0.11(-0.05,0.28) P=0.149	β (95% CI), P- valu Reference 0.03(-0.11,0.17) P=0.643	e β (95% CI), Referen 0.02(-0.12 P=0.74	P- value nce 2,0.17) 40
33 34 35 36 37 38		No periodontitis	1142/2149	β (95% CI), P- value Reference 0.11(-0.05,0.28)	β (95% CI), P- valu Reference 0.03(-0.11,0.17)	e β (95% CI), Referen 0.02(-0.12	P- value nce 2,0.17) 40 3,0.41)
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> </ul>		No periodontitis Mild–moderate periodontitis Severe periodontitis AAC-24 score	1142/2149 787/2149 220/2149	β (95% CI), P- value Reference 0.11(-0.05,0.28) P=0.149 <b>0.29( 0.08,0.50)</b> <b>P=0.015</b>	$\begin{array}{c} \beta \ (95\% \ CI), \ P- \ value \\ Reference \\ 0.03(-0.11, 0.17) \\ P=0.643 \\ 0.17(-0.07, 0.41) \\ P=0.159 \end{array}$	e β (95% CI), Referen 0.02(-0.12 P=0.74 0.17(-0.08 P=0.17	P- value nce 2,0.17) 40 3,0.41) 73
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> <li>41</li> </ul>		No periodontitis Mild–moderate periodontitis Severe periodontitis AAC-24 score No periodontitis	1142/2149 787/2149 220/2149 1142/2149	β (95% CI), P- value Reference 0.11(-0.05,0.28) P=0.149 <b>0.29( 0.08,0.50)</b>	$\beta (95\% \text{ CI}), P- \text{ value}$ Reference $0.03(-0.11, 0.17)$ $P=0.643$ $0.17(-0.07, 0.41)$	e β (95% CI), Referen 0.02(-0.12 P=0.74 0.17(-0.08	P- value nce 2,0.17) 40 3,0.41) 73
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> </ul>		No periodontitis Mild–moderate periodontitis Severe periodontitis <b>AAC-24 score</b> No periodontitis Mild–moderate periodontitis	1142/2149 787/2149 220/2149 1142/2149 787/2149	$\frac{\beta (95\% \text{ CI}), \text{ P- value}}{\text{Reference}}$ $0.11(-0.05, 0.28)$ $P=0.149$ $0.29( 0.08, 0.50)$ $P=0.015$ $Reference$ $0.34(-0.10, 0.78)$ $P=0.110$	$\begin{array}{c} \beta \ (95\% \ CI), \ P\ value \\ \hline Reference \\ 0.03(-0.11, 0.17) \\ P=0.643 \\ 0.17(-0.07, 0.41) \\ P=0.159 \\ \hline Reference \\ 0.15(-0.22, 0.52) \\ P=0.393 \end{array}$	e β (95% CI), Referen 0.02(-0.12 P=0.74 0.17(-0.08 P=0.17 Referen 0.14(-0.26 P=0.47	P- value nce 2,0.17) 40 3,0.41) 73 nce 5,0.54) 72
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> <li>41</li> <li>42</li> <li>43</li> <li>44</li> </ul>		No periodontitis Mild–moderate periodontitis Severe periodontitis AAC-24 score No periodontitis	1142/2149 787/2149 220/2149 1142/2149	$\frac{\beta (95\% \text{ CI}), \text{ P- value}}{\text{Reference}}$ $0.11(-0.05, 0.28)$ $P=0.149$ $0.29( 0.08, 0.50)$ $P=0.015$ $Reference$ $0.34(-0.10, 0.78)$	$\frac{\beta (95\% \text{ CI}), \text{ P- value}}{\text{Reference}}$ $\frac{0.03(-0.11, 0.17)}{P=0.643}$ $\frac{0.17(-0.07, 0.41)}{P=0.159}$ Reference 0.15(-0.22, 0.52)	e β (95% CI), Referen 0.02(-0.12 P=0.74 0.17(-0.08 P=0.17 Referen 0.14(-0.26	P- value nce 2,0.17) 40 3,0.41) 73 nce 5,0.54) 72 2,1.17)
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> <li>41</li> <li>42</li> <li>43</li> </ul>	215	No periodontitis Mild–moderate periodontitis Severe periodontitis <b>AAC-24 score</b> No periodontitis Mild–moderate periodontitis	1142/2149 787/2149 220/2149 1142/2149 787/2149 220/2149	$\frac{\beta (95\% \text{ CI}), \text{ P- value}}{\text{Reference}}$ $0.11(-0.05, 0.28)$ $P=0.149$ $0.29( 0.08, 0.50)$ $P=0.015$ $Reference$ $0.34(-0.10, 0.78)$ $P=0.110$ $0.80( 0.25, 1.34)$ $P=0.011$	$\begin{array}{c} \beta \ (95\% \ CI), \ P\ value \\ \hline Reference \\ 0.03(-0.11,0.17) \\ P=0.643 \\ 0.17(-0.07,0.41) \\ P=0.159 \\ \hline Reference \\ 0.15(-0.22,0.52) \\ P=0.393 \\ 0.57(-0.01,1.14) \\ P=0.052 \end{array}$	e $β$ (95% CI), Referen 0.02(-0.12 P=0.74 0.17(-0.08 P=0.17 Referen 0.14(-0.26 P=0.47 0.58(-0.02 P=0.02)	P- value nce 2,0.17) 40 2,0.41) 73 nce 0,0.54) 72 2,1.17) 56
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> <li>41</li> <li>42</li> <li>43</li> <li>44</li> <li>45</li> <li>46</li> <li>47</li> <li>48</li> </ul>	215 216	No periodontitis Mild–moderate periodontitis Severe periodontitis <b>AAC-24 score</b> No periodontitis Mild–moderate periodontitis Severe periodontitis	1142/2149 787/2149 220/2149 1142/2149 787/2149 220/2149 20/2149	$\frac{\beta (95\% \text{ CI}), \text{ P- value}}{\text{Reference}}$ 0.11(-0.05,0.28) P=0.149 0.29( 0.08,0.50) P=0.015 Reference 0.34(-0.10,0.78) P=0.110 0.80( 0.25,1.34) P=0.011 ce; Model 2 was adjus	$\frac{\beta (95\% \text{ CI}), \text{ P- value}}{\text{Reference}}$ 0.03(-0.11,0.17) P=0.643 0.17(-0.07,0.41) P=0.159 Reference 0.15(-0.22,0.52) P=0.393 0.57(-0.01,1.14) P=0.052 eted for the parameters	e β (95% CI), Referen 0.02(-0.12 P=0.74 0.17(-0.08 P=0.17 Referen 0.14(-0.26 P=0.42 0.58(-0.02 P=0.02 S in Model 1 plus i	P- value nce 2,0.17) 40 3,0.41) 73 nce 5,0.54) 72 2,1.17) 56 insurance,
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> <li>41</li> <li>42</li> <li>43</li> <li>44</li> <li>45</li> <li>46</li> <li>47</li> <li>48</li> <li>49</li> <li>50</li> </ul>		No periodontitis Mild–moderate periodontitis Severe periodontitis <b>AAC-24 score</b> No periodontitis Mild–moderate periodontitis Severe periodontitis Note: Model 1 was adjusted for	1142/2149 787/2149 220/2149 1142/2149 787/2149 220/2149 For age, sex, and ra	$\frac{\beta (95\% \text{ CI}), \text{ P- value}}{\text{Reference}}$ 0.11(-0.05,0.28) P=0.149 0.29( 0.08,0.50) P=0.015 Reference 0.34(-0.10,0.78) P=0.110 0.80( 0.25,1.34) P=0.011 ce; Model 2 was adjus mption status, PIR, B	$\frac{\beta (95\% \text{ CI}), \text{ P- value}}{\text{Reference}}$ Reference 0.03(-0.11,0.17) P=0.643 0.17(-0.07,0.41) P=0.159 Reference 0.15(-0.22,0.52) P=0.393 0.57(-0.01,1.14) P=0.052 sted for the parameters MI, diabetes, hyperte	e $β (95\% CI),$ Referen 0.02(-0.12 P=0.7- 0.17(-0.08 P=0.1' Referen 0.14(-0.26 P=0.4' 0.58(-0.02 P=0.03 s in Model 1 plus in nsion, CVD and 0	P- value nce (0.17) 40 (0.41) 73 nce (0.54) 72 (1.17) 56 insurance, CKD; and
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> <li>41</li> <li>42</li> <li>43</li> <li>44</li> <li>45</li> <li>46</li> <li>47</li> <li>48</li> <li>49</li> <li>50</li> <li>51</li> <li>52</li> <li>53</li> </ul>	216	No periodontitis Mild-moderate periodontitis Severe periodontitis <b>AAC-24 score</b> No periodontitis Mild-moderate periodontitis Severe periodontitis Note: Model 1 was adjusted feeducation level, smoking stat	1142/2149 787/2149 220/2149 1142/2149 787/2149 220/2149 For age, sex, and ra tus, alcohol consu	$\frac{\beta (95\% \text{ CI}), \text{ P- value}}{\text{Reference}}$ 0.11(-0.05,0.28) P=0.149 0.29( 0.08,0.50) P=0.015 Reference 0.34(-0.10,0.78) P=0.110 0.80( 0.25,1.34) P=0.011 ce; Model 2 was adjus mption status, PIR, B odel 2 plus albumin, so	$\frac{\beta (95\% \text{ CI}), \text{ P- value}}{\text{Reference}}$ Reference 0.03(-0.11,0.17) P=0.643 0.17(-0.07,0.41) P=0.159 Reference 0.15(-0.22,0.52) P=0.393 0.57(-0.01,1.14) P=0.052 eted for the parameters MI, diabetes, hyperte erum calcium, serum	e β (95% CI), Referen 0.02(-0.12 P=0.74 0.17(-0.08 P=0.17 Referen 0.14(-0.26 P=0.47 0.58(-0.02 P=0.02 s in Model 1 plus i nsion, CVD and 0 phosphorus, uric	P- value nce (0.17) 40 (0.41) 73 nce (0.54) 72 (1.17) 56 insurance, CKD; and
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> <li>41</li> <li>42</li> <li>43</li> <li>44</li> <li>45</li> <li>46</li> <li>47</li> <li>48</li> <li>49</li> <li>50</li> <li>51</li> <li>52</li> <li>53</li> <li>54</li> <li>55</li> </ul>	216 217	No periodontitis Mild-moderate periodontitis Severe periodontitis <b>AAC-24 score</b> No periodontitis Mild-moderate periodontitis Severe periodontitis Note: Model 1 was adjusted for education level, smoking stat Model 3 was adjusted for the	1142/2149 787/2149 220/2149 1142/2149 787/2149 220/2149 For age, sex, and ra tus, alcohol consu parameters in Mo globin, TC, HDL-	β (95% CI), P- value Reference 0.11(-0.05,0.28) P=0.149 0.29( 0.08,0.50) P=0.015 Reference 0.34(-0.10,0.78) P=0.110 0.80( 0.25,1.34) P=0.011 ce; Model 2 was adjus mption status, PIR, B odel 2 plus albumin, se C, and TGs. AAC: ab	$\frac{\beta (95\% \text{ CI}), \text{ P- value}}{\text{Reference}}$ $\frac{0.03(-0.11,0.17)}{P=0.643}$ $0.17(-0.07,0.41)$ $P=0.159$ Reference $0.15(-0.22,0.52)$ $P=0.393$ $0.57(-0.01,1.14)$ $P=0.052$ sted for the parameters MI, diabetes, hyperte erum calcium, serum dominal aortic calcified	e β (95% CI), Referen 0.02(-0.12 $P=0.7^2$ 0.17(-0.08 $P=0.1^2$ Referen 0.14(-0.26 $P=0.4^2$ 0.58(-0.02 P=0.03 s in Model 1 plus i nsion, CVD and 0 phosphorus, uric ccation.	P- value nce (0.17) 40 (0.41) 73 nce (0.54) 72 (1.17) 56 insurance, CKD; and acid, total
<ul> <li>33</li> <li>34</li> <li>35</li> <li>36</li> <li>37</li> <li>38</li> <li>39</li> <li>40</li> <li>41</li> <li>42</li> <li>43</li> <li>44</li> <li>45</li> <li>46</li> <li>47</li> <li>48</li> <li>49</li> <li>50</li> <li>51</li> <li>52</li> <li>53</li> <li>54</li> </ul>	216 217 218	No periodontitis Mild-moderate periodontitis Severe periodontitis <b>AAC-24 score</b> No periodontitis Mild-moderate periodontitis Severe periodontitis Note: Model 1 was adjusted fe education level, smoking stat Model 3 was adjusted for the 25-hydroxyvitamin D, hemog	1142/2149 787/2149 220/2149 1142/2149 787/2149 220/2149 For age, sex, and ra tus, alcohol consu parameters in Mo globin, TC, HDL- association betw	$\frac{\beta (95\% \text{ CI}), \text{ P- value}}{\text{Reference}} \\ 0.11(-0.05, 0.28) \\ P=0.149 \\ \textbf{0.29} (\textbf{0.08, 0.50}) \\ \textbf{P=0.015} \\ \text{Reference} \\ 0.34(-0.10, 0.78) \\ P=0.110 \\ \textbf{0.80} (\textbf{0.25, 1.34}) \\ \textbf{P=0.011} \\ \text{ce; Model 2 was adjus} \\ \text{mption status, PIR, Bill odel 2 plus albumin, see C, and TGs. AAC: ab} \\ \text{ween periodontitis a status} \\ \text{results of the status} \\ resu$	$\frac{\beta (95\% \text{ CI}), \text{ P- value}}{\text{Reference}}$ $\frac{0.03(-0.11,0.17)}{P=0.643}$ $0.17(-0.07,0.41)$ $P=0.159$ Reference $0.15(-0.22,0.52)$ $P=0.393$ $0.57(-0.01,1.14)$ $P=0.052$ where the parameters of the para	e $β$ (95% CI), Referen 0.02(-0.12 P=0.74 0.17(-0.08 P=0.17 Referen 0.14(-0.26 P=0.47 0.58(-0.02 P=0.02 s in Model 1 plus i nsion, CVD and 0 phosphorus, uric cation. the multivariate	P- value nce 2,0.17) 40 2,0.41) 73 nce 5,0.54) 72 2,1.17) 56 insurance, CKD; and acid, total e logistic

#### **BMJ** Open

1 2 3	221	in the high-AAC risk group (AAC-8 score $\geq$ 3 points) (OR: 2.53; 95% CI 1.04, 6.17) compared with
4 5	222	the low-AAC risk group (AAC-8 score < 3 points). The degree of periodontitis and AAC as defined
6 7	223	by the more refined AAC-24 score were further analyzed. Mild-moderate and severe periodontitis were
8 9 10	224	associated with an increased prevalence of severe AAC (OR: 2.25; 95% CI 1.24, 4.06 and OR: 3.60;
10 11 12	225	95% CI 1.48, 8.78) relative to participants without AAC. Furthermore, this association remained when
13 14	226	participants with mild-moderate AAC were replaced with a reference population; mild-moderate and
15 16 17	227	severe periodontitis were associated with severe AAC (OR: 2.28; 95% CI 1.28, 4.06 and OR: 2.93;
17 18 19	228	95% CI 1.28, 6.69). In addition, no correlation was found between periodontitis and mild-moderate
20 21	229	AAC.
22		

TABLE 3 Weighted multiple logistic regression coefficients (ORs) and 95% confidence intervals for the association between periodontal status with AAC group: The United States, 2013 to 2014

AAC-8 score ≥ 3 points versus	S	OR (95% CI), P- value	OR (95% CI), P- value	OR (95% CI), P- va
No periodontitis	46/1142	Reference	Reference	Reference
Mild-moderate periodontitis	66/787	2.07(1.01,4.22) P=0.047	1.79(0.95,3.38) P=0.069	1.84(1.00,3.40) P=0.051
Severe periodontitis	19/220	3.20(1.22,8.40) P=0.025	2.53(1.05,6.11) P=0.040	2.53(1.04,6.17) P=0.043
Mild–moderate AAC versus no	AAC			
No periodontitis	224/1102	Reference	Reference	Reference
Mild-moderate periodontitis	144/723	0.89(0.58,1.38) P=0.561	0.76(0.53,1.08) P=0.113	0.72(0.51,1.02) P=0.061
Severe periodontitis	50/200	1.46(0.79,2.68) P=0.185	1.05(0.52,2.10) P=0.886	0.96(0.48,1.93) P=0.914
Severe AAC versus no AAC		1 0.100	1 0.000	1 0.011
No periodontitis	40/918	Reference	Reference	Reference
Mild–moderate periodontitis	64/643	2.57(1.35, 4.89) P=0.010	2.19(1.23,3.89) P=0.011	2.25(1.24,4.06) P=0.011
Severe periodontitis	20/170	6.13(2.55,14.72) P=0.002	3.62(1.63,8.06) P=0.004	3.60(1.48,8.78) P=0.008
Severe AAC versus mild-mode	rate AAC			
No periodontitis	40/264	Reference	Reference	Reference
Mild-moderate periodontitis	64/208	2.59(1.49,4.52) P=0.005	2.20(1.27,3.80) P=0.008	2.28(1.28, 4.06) P=0.008
Severe periodontitis	20/70	3.16(1.21,8.22) P=0.025	2.89(1.27,6.60) P=0.015	2.93(1.28, 6.69) P=0.014

Model 3 was adjusted for the parameters in Model 2 plus albumin, serum calcium, serum phosphorus, uric acid, total

235 25-hydroxyvitamin D, hemoglobin, TC, HDL-C, and TGs. No AAC, mild-moderate AAC and Severe AAC were
236 defined by AAC-24 score. AAC: abdominal aortic calcification.

In the subgroup analysis (Table 4), we investigated the association between periodontitis and severe AAC based on an AAC-8 score  $\geq$  3. We found that the likelihood ratio test for multiplicative interactions was not statistically significant for age, sex, CVD, hypertension, diabetes, or CKD after adjustment for potential confounders (P interaction > 0.05). Thus, we did not find any substantial evidence to demonstrate systematic differences in associations between different subpopulations in the population, indicating that our main results were stable.

**TABLE 4** Subgroup analysis for the association between periodontal status and risk of severe AAC (AAC-8 score

  $\geq$  3 points).

		Periodontal statu DR (95% CI), P- val		
	No periodontitis	Mild–moderate periodontitis	Severe periodontitis	P for interaction
Age				0.212
≥60y	Reference	1.90(0.88,4.11) P=0.096	5.66(1.15,27.92) P=0.035	
<60y	Reference	3.44(0.83,14.15) P=0.083	1.58(0.24,10.43) P=0.611	
Gender				0.207
Male	Reference	1.90(0.55,6.56) P=0.285	4.40(1.09,17.85) P=0.039	
Female	Reference	2.37(1.42,3.93) P=0.003	0.92(0.29,2.94) P=0.876	
Cardiovascular diseases				0.381
Yes	Reference	1.61(0.31,8.35) P=0.548	NA*	
No	Reference	1.95(1.02,3.73) P=0.044	2.14(0.86,5.35) P=0.096	
Diabetes				0.837
Yes	Reference	4.00(1.49,10.69) P=0.009	9.64(1.45,64.16)* P=0.022	
No	Reference	1.51(0.67,3.40) P=0.293	2.21(0.76,6.44) P=0.136	
Hypertension				0.085
Yes	Reference	1.81(0.88, 3.74) P=0.099	3.39(1.35, 8.56) P=0.013	
No	Reference	3.27(1.08, 9.91) P=0.037	0.73(0.08, 6.72) P=0.767	
Chronic kidney disease				0.501
Yes	Reference	2.20(1.15, 4.21) P=0.021	1.57(0.22, 11.17) P=0.630	
No	Reference	1.81(0.79, 4.12)	2.98(1.21, 7.34)	

#### For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### **BMJ** Open

2		P=0.147 <b>P=0.020</b>
3 4	245	Note: All presented covariates were adjusted (as Model 3) except the corresponding stratification variable. *Wide CI
5 6 7	246	and no production OR are due to the small sample size for this comparison.
8 9	247	In the primary study, we imputed missing covariates (the proportions of all missing variables were
10 11 12	248	less than 5.00% except for the PIR, at 8.19%) using the MissForest package. The random forest analysis
13 14	249	had a seed number of 500 and completed data imputation after eight iterations. Model performance
15 16	250	indicators normalized root mean squared error computed (NRMSE) was 0.578 and proportion of falsely
17 18	251	classified (PFC) was 0.336. In the sensitivity analysis, we excluded participants with missing
19 20 21	252	covariates, and we included 1,818 individuals with complete data in the subsequent analyses. The
22 23	253	baseline distribution of participant characteristics did not differ significantly from that in the previously
24 25	254	included population, but it was worth mentioning that the prevalence of severe AAC with severe
26 27 28	255	periodontitis have decreased by approximately 1% (Supplementary Material Table 2). Further logistic
28 29 30	256	regression analysis showed, our result regarding the association of periodontitis and AAC differed from
31 32	257	that in the primary analysis. In Model 3, only mild-moderate periodontitis was associated with an
33 34	258	increased risk of severe AAC (OR: 1.89; 95% CI 1.01, 3.56), and the remaining associations were
35 36 37	259	attenuated or had disappeared (Supplementary Material Table 3). When we decoupled mild-moderate
38 39	260	periodontitis and excluded participants with mild periodontitis, the results of the sensitivity analysis
40 41	261	were similar to those of the main analysis (Supplementary Material Table 4). It is worth mentioning
42 43 44	262	that mild-moderate periodontitis was associated with a reduced prevalence of mild to moderate AAC
45 46	263	in participants without CVD, and the association of severe periodontitis with AAC in the high-AAC
47 48 49	264	risk group (AAC-8 scores $\geq$ 3 points) disappeared (Supplementary Material Table 5).

#### 4. Discussion

To our knowledge, this is the first population-based cross-sectional epidemiological study to explore the link between periodontitis and AAC in a nationally representative sample of U.S. adults 

(40 years and older). Our study fully considered socioeconomic status, behavioral factors and medical history of the participants and controlled for a wide range of confounders. Severe periodontitis was positively associated with severe AAC, defined by either the AAC-8 score or AAC-24 score. A positive association between mild to moderate periodontitis and severe AAC was found only when AAC was classified by the AAC-24 score. In the subgroups stratified by age; sex; and CVD, hypertension, diabetes, and CKD status, this association and the main results were generally consistent; the only difference was associated with the different severities of periodontitis, which differed in their associations with severe AAC in the stratified population. Linear regression evaluation of the AAC-8 score and AAC-24 score as dependent variables and the different severities of periodontitis as independent variables showed no linear correlation. In the sensitivity analysis, the association remained significant after excluding participants with mild periodontitis and CVD. However, the association was no longer significant after excluding participants with missing covariates.

To date, some epidemiological studies have suggested a close relationship between periodontitis and vascular calcification or CVD. A consensus report on periodontitis and CVD states that periodontitis is broadly associated with CVD and that the link is bidirectional; CVD drives the progression of periodontitis and vice versa<sup>39</sup>. NHANES-based cross-sectional studies have shown an association between periodontitis severity and cardiovascular risk<sup>4</sup>, as demonstrated by the results of a 13-year cohort study, and further studies suggest that periodontitis may be an independent risk factor for  $CVD^{40}$ . Oindrila Paul et al. reviewed the pathophysiology of periodontitis and showed that inflammation associated with periodontitis may be the main mechanism affecting CVD and could be facilitated by common risk factors<sup>41</sup>. Vascular calcification has been shown to involve soft tissue calcification also caused by chronic inflammatory stimuli<sup>19</sup> and is closely related to the prevalence and prognosis of CVD. This may suggest that the association between periodontitis and CVD may depend on the severity of vascular calcification. The results of a cross-sectional Japanese population-based 

Page 17 of 34

#### **BMJ** Open

study suggest that measuring alveolar bone loss on panoramic radiographs may be an effective method to identify an increased risk of carotid artery calcification<sup>14</sup>. Imaging studies using cone-beam computed tomography have further confirmed that the development of periodontitis may cause calcification involving the intracranial carotid arteries<sup>16</sup>. The results from a meta-analysis that included 12 studies also revealed a significant relationship between periodontitis and carotid artery calcification<sup>15</sup>. Similar to our findings, a cohort study in Chinese populations suggested that periodontitis was also positively associated with aortic calcification, and this association was more pronounced in men and in participants younger than 65 years<sup>13</sup>. 

The exact mechanism of the link between periodontitis and AAC remains unclear and needs to be further explored. Existing mainstream views suggest that *Porphyromonas gingivalis* (*P. gingivalis*) infection and chronic inflammation are important bridges between periodontitis and vascular calcification<sup>19, 41-42</sup>. Recent studies have shown that periodontal pathogens can be detected in the blood of patients with coronary heart disease, and it is hypothesized that periodontal pathogens can spread through the blood to other parts of the body, where they may enhance inflammatory processes, leading to the development or aggravation of atherosclerosis<sup>43</sup>. Evidence from in vitro cell culture studies suggests that *P. gingivalis* infection accelerates phosphate-induced calcification of vascular smooth muscle cells<sup>22</sup> and that *P. gingivalis* lipopolysaccharide increases alkaline phosphatase activity and upregulates the expression of genes involved in calcification to stimulate calcification<sup>44</sup>. In addition, it has been shown that *P. gingivalis* invasiveness is enhanced after high-glucose treatment, and vascular calcification can be initiated by stimulating autocrine regulation of bone morphogenetic protein 4 in aortic smooth muscle cells<sup>21</sup>. P. gingivalis infection elicits an inflammatory response in the host, which is in line with the definition of periodontitis as a chronic inflammatory disease. A meta-analysis suggested that the diagnosis of chronic aggressive periodontitis was consistently associated with higher C-reactive protein and high-sensitivity C-reactive protein levels, and treatment reduced serum C-

BMJ Open: first published as 10.1136/bmjopen-2022-068931 on 15 March 2023. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright

reactive protein levels<sup>45</sup>. In addition, studies have observed an association between periodontitis and systemic inflammation, which increases with the severity of periodontal disease<sup>46</sup>. Notably, there are studies revealing other possible mechanisms involved in the link between periodontitis and vascular calcification, including the activation of osteoprotegerin/receptor activator of nuclear factor- $\kappa$ B ligand and endoplasmic reticulum stress-induced apoptosis<sup>23-24</sup>.

Our study has several important strengths. Our findings were derived from a large nationwide random sample survey and can be generalized to the adult noninstitutionalized population in the U.S. Periodontitis and AAC were defined based on objective clinical data collected by calibrated professionals. In addition, this study addressed a number of known potential confounders, and sample weights were applied in each analysis following the NHANES guidelines to account for the complex survey design. However, several limitations of this study warrant attention. Given the cross-sectional design of the NHANES, it is difficult for us to determine causality, and further large-scale prospective studies are needed. In addition, we cannot exclude the possibility of residual confounding by other confounding factors related to oral health, which could have influenced the observed results. It is worth noting that only a small proportion of patients with severe periodontitis in our study had severe AAC; perhaps because of this, the results of the sensitivity analysis excluding patients with missing covariates were not robust. This also suggests that the conclusions of this study should be interpreted with caution. An explanation for this phenomenon is the possibility of selection bias<sup>47</sup>. In addition, tooth loss is not considered in the CDC/AAP case definition of periodontitis; therefore, the prevalence of the disease may be underestimated<sup>30</sup>. Because of the sample size, we were not able to include the new periodontal profile class (PPC) system to precisely classify periodontal disease because this classification method classifies periodontitis into seven categories: PPC-A to PPC-G<sup>48</sup>.

**338 5. Conclusion** 

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### **BMJ** Open

	<u>ω</u>
	Ş
	こ 0
	$\underline{\circ}$
	8
	Ľ
	<u></u>
	Ŧ
	ŝ
	σ
	É
	<u>o</u>
	<u>0</u> .
	₹
	shed as 10
	~
	S
	_
	5
	-
	-
	ω
	ত
	₫
	3
	<u>o</u> .
	Ō
	₫.
	<u>.</u>
	2
	ы
	ijopen-2022-068931 on 15 M
	Y
	ത്
	58931 on 15 March 2023. Downli
	õ
	5
	~
	4
	~
	σī
	_
	≦
	<u>ه</u>
	<u>o</u>
	⊐
	N
	ch 202
	ω
	023. D
	σ
	2
	≧
	_
	_
	<u></u>
	loac
	loade
	loaded
	loaded fr
	loaded froi
	loaded from
	loaded from h
	loaded from http
-	loaded from http:
-	paded from http:/
-	loaded from http://bmjopen.t
-	paded from http:/
-	paded from http://bmjopen.bmj.com/ on April 20,
-	paded from http://bmjopen.bmj.com/ on April 20, 2
-	paded from http:/
-	paded from http://bmjopen.bmj.com/ on April 20, 2
-	paded from http://bmjopen.bmj.com/ on April 20, 2
-	paded from http://bmjopen.bmj.com/ on April 20, 2
-	paded from http://bmjopen.bmj.com/ on April 20, 2
-	paded from http://bmjopen.bmj.com/ on April 20, 2
-	paded from http://bmjopen.bmj.com/ on April 20, 2
-	paded from http://bmjopen.bmj.com/ on April 20, 2
-	paded from http://bmjopen.bmj.com/ on April 20, 2024 by guest.
-	paded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Pr
-	paded from http://bmjopen.bmj.com/ on April 20, 2024 by guest.
-	paded from http://bmjopen.bmj.com/ on April 20, 2024 by quest. Prote
-	paded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Prot
-	paded from http://bmjopen.bmj.com/ on April 20, 2024 by quest. Protecte
-	paded from http://bmjopen.bmj.com/ on April 20, 2024 by quest. Prote
-	paded from http://bmjopen.bmj.com/ on April 20, 2024 by quest. Protecte
-	paded from http://bmjopen.bmj.com/ on April 20, 2024 by quest. Protecte
-	paded from http://bmjopen.bmj.com/ on April 20, 2024 by quest. Protecte
-	paded from http://bmjopen.bmj.com/ on April 20, 2024 by quest. Protecte
-	paded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by co
-	paded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by co
-	paded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by co

Our study suggests that periodontitis is associated with an increased risk of severe AAC in the U.S. population aged 40 years and older. The associations investigated in this study are credible due to their cross-sectional nature, but these findings require further large-scale prospective studies to confirm. Acknowledgements The authors gratefully acknowledge the financial supports by the the Construction of key laboratories in Xinjiang Uygur Autonomous Region (Grant No. 2019D04017) and Tianshan Cedar Program (Grant No. 2020XS13). Furthermore, We thank all members of the NHANES teams for surveys and data collection throughout the United States. **Contributors** KK, AnA and AiA participated in the design of the study, analysis of the data and drafted the manuscript or revised it for important content. RR collected and organized data. XM and Y-TM contributed to the conception and design of the manuscript as well as reviewing critical modifications for important intellectual content. Funding This study was supported by the Construction of key laboratories in Xinjiang Uygur Autonomous Region (Grant No. 2019D04017) and Tianshan Cedar Program (Grant No. 2020XS13). **Competing interests** None declared. Patient consent for publication 

2 3 4	359	The
5 6 7	360	Ethics ap
8 9 10	361	The
11 12	362	NCHS R
13 14 15	363	Protocol #
16 17 18 19	364	Data avai
20 21 22	365	This
23 24 25	366	found on
26 27 28 29	367	
30 31	368	1. Chen N
32 33	369	severe pe
34 35 36	370	Periodoni
37 38 39	371	2. Eke PI,
40 41 42	372	NHANES
43 44 45	373	3. Van Dy
46 47 48	374	future car
49 50	375	4. Sumayi
51 52 53 54	376	Disease an
55 56		
57		
58 59		
60		

participants provided written informed consent to participate in the NHANES survey.

## proval

1

present study complied with the term of the Declaration of Helsinki and was approved by the esearch Ethics Review Committee (NCHS IRB/ERB Protocol Number: Continuation of #2011-17).

## ilability statement

study is a secondary analysis based on a publicly available database and the raw data can be the website: https://www.cdc.gov/nchs/nhanes/index.htm

## References

MX, Zhong YJ, Dong QQ, Wong HM, Wen YF. Global, regional, and national burden of riodontitis, 1990-2019: An analysis of the Global Burden of Disease Study 2019. J Clin tol. 2021;48:1165-1188.

Dye BA, Wei L, et al. Update on Prevalence of Periodontitis in Adults in the United States: S 2009 to 2012. J Periodontol. 2015;86:611-622.

yke TE, Kholy KE, Ishai A, et al. Inflammation of the periodontium associates with risk of diovascular events. J Periodontol. 2021;92:348-358.

in Ngamdu K, Mallawaarachchi I, Dunipace EA, et al. Association Between Periodontal

nd Cardiovascular Disease (from the NHANES). Am J Cardiol. 2022;178:163-168.

1 2 2	377	5. Genco RJ, Graziani F, Hasturk H. Effects of periodontal disease on glycemic control, complications,
3 4 5 6	378	and incidence of diabetes mellitus. Periodontol 2000. 2020;83:59-65.
7 8	379	6. Parsegian K, Randall D, Curtis M, Ioannidou E. Association between periodontitis and chronic
9 10 11	380	kidney disease. Periodontol 2000. 2022;89:114-124.
12 13 14	381	7. Romandini M, Baima G, Antonoglou G, Bueno J, Figuero E, Sanz M. Periodontitis, Edentulism,
15 16 17	382	and Risk of Mortality: A Systematic Review with Meta-analyses. J Dent Res. 2021;100:37-49.
18 19	383	8. Eke PI, Thornton-Evans G, Dye B, Genco R. Advances in surveillance of periodontitis: the Centers
20 21 22	384	for Disease Control and Prevention periodontal disease surveillance project. J Periodontol.
23 24	385	2012;83:1337-1342.
25 26 27	386	9. Fiz F, Piccardo A, Morbelli S, et al. Longitudinal analysis of atherosclerotic plaques evolution:
28 29 30	387	an <sup>18</sup> F-NaF PET/CT study. J Nucl Cardiol. 2022;29:1713-1723.
31 32	388	10. Wilson PW, Kauppila LI, O'Donnell CJ, et al. Abdominal aortic calcific deposits are an important
33 34 35	389	predictor of vascular morbidity and mortality. Circulation. 2001;103:1529-1534.
36 37 38	390	11. Górriz JL, Molina P, Cerverón MJ, et al. Vascular calcification in patients with nondialysis CKD
39 40 41	391	over 3 years. <i>Clin J Am Soc Nephrol</i> . 2015;10:654-666.
42 43	392	12. Bendix EF, Johansen E, Ringgaard T, Wolder M, Starup-Linde J. Diabetes and Abdominal Aortic
44 45		
46 47 48	393	Calcification-a Systematic Review. Curr Osteoporos Rep. 2018;16:42-57.
49 50	394	13. Yu YL, Ma JR, Li SN, et al. Association between Periodontitis and Aortic Calcification: A Cohort
51 52 53	395	Study. Angiology. 2022;33197221094713.
54 55		
56 57 58		
58 59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 20

BMJ Open: first published as 10.1136/bmjopen-2022-068931 on 15 March 2023. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright

#### **BMJ** Open

396 14. Dewake N, Ishioka Y, Uchida K, et al. Association between Carotid Artery Calcification and
397 Periodontal Disease Progression in Japanese Men and Women: A Cross-Sectional Study. *J Clin Med.*398 2020;9:3365.

399 15. Wang W, Yang Z, Wang Y, Gao H, Wang Y, Zhang Q. Association between Periodontitis and
400 Carotid Artery Calcification: A Systematic Review and Meta-Analysis. *Biomed Res Int.*401 2021;2021:3278351.

402 16. AlSakr A, Blanchard S, Wong P, Thyvalikakath T, Hamada Y. Association between intracranial
403 carotid artery calcifications and periodontitis: A cone-beam computed tomography study. J
404 *Periodontol.* 2021;92:1402-1409.

405 17. Nakib SA, Pankow JS, Beck JD, et al. Periodontitis and coronary artery calcification: the
406 Atherosclerosis Risk in Communities (ARIC) study. *J Periodontol*. 2004;75:505-510.

407 18. Hujoel PP, Drangsholt M, Spiekerman C, DeRouen TA. Periodontal disease and coronary heart 45 408 disease risk. *JAMA*. 2000;284:1406-1410.

409 19. Li JJ, Zhu CG, Yu B, Liu YX, Yu MY. The role of inflammation in coronary artery 410 calcification. *Ageing Res Rev.* 2007;6:263-270.

411 20. Li H, Pan K, Meng Y, et al. Mutual promotions between periodontitis and vascular calcification by
5 412 rat animal model. *J Periodontal Res.* 2020;55:810-820.

413 21. Chen TC, Lin CT, Chien SJ, Chang SF, Chen CN. Regulation of calcification in human aortic
 414 smooth muscle cells infected with high-glucose-treated Porphyromonas gingivalis. *J Cell Physiol.* 415 2018;233:4759-4769.

60

## BMJ Open

찔
BMJ O
Q
en
Ē
rst
ри
blis
she
ă
as
10
36
/br
-ji
pe
, ,
202
)pen: first published as 10.1136/bmjopen-2022-068931 on 15 March 2023. Downloaded from h
6
89
<u> </u>
9
15 M
lar
S
2023
23
ð
nlo
ac
lec
fr
m
Ę.
b
omjope
ğ
ň.
- b
. <u>p</u>
mo
0
∩ ≁
þr
ii N
,
22
~
)24
)24 by
)24 by gu
)24 by gues
)24 by guest. F
)24 by guest. Pro
)24 by guest. Protec
)24 by guest. Protected
)24 by guest. Protected b
)24 by guest. Protected by c
)24 by guest. Protected by cop
024 by guest. Protected by copyri
)24 by guest. Protected by copyright

1		
1 2 3	416	22. Park HJ, Kim Y, Kim MK, et al. Infection of Porphyromonas gingivalis Increases Phosphate-
5 4 5 6	417	Induced Calcification of Vascular Smooth Muscle Cells. Cells. 2020;9:2694.
7 8	418	23. Jiao M, Zhang P, Yu X, et al. Osteoprotegerin/receptor activator of nuclear factor-κB ligand are
9 10 11	419	involved in periodontitis-promoted vascular calcification. Exp Ther Med. 2022;24:512.
12 13 14	420	24. Song X, Li J, Jiao M, Chen Y, Pan K. Effect of endoplasmic reticulum stress-induced apoptosis in
15 16 17	421	the role of periodontitis on vascular calcification in a rat model. J Mol Histol. 2021;52:1097-1104.
18 19 20	422	25. Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW. New indices to classify
20 21 22	423	location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up
23 24 25	424	study. Atherosclerosis. 1997;132:245-250.
26 27 28	425	26. Criqui MH, Denenberg JO, McClelland RL, et al. Abdominal aortic calcium, coronary artery
20 29 30	426	calcium, and cardiovascular morbidity and mortality in the Multi-Ethnic Study of
30 31 32 33	427	Atherosclerosis. Arterioscler Thromb Vasc Biol. 2014;34:1574-1579.
34 35	428	27. Johnson CL, Dohrmann SM, Burt VL, Mohadjer LK. National health and nutrition examination
36 37 38	429	survey: sample design, 2011-2014. Vital Health Stat 2. 2014;162:1-33.
39 40 41	430	28. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies
42 43	431	in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet.
44 45 46	432	2007;370:1453-1457.
47 48 49	433	29. Dye BA, Afful J, Thornton-Evans G, Iafolla T. Overview and quality assurance for the oral health
50 51	434	component of the National Health and Nutrition Examination Survey (NHANES), 2011-2014. BMC
52 53 54	435	<i>Oral Health.</i> 2019;19:95.
55 56		
57 58		

2 3	436	30. Eke PI, Page RC, Wei L, Thornton-Evans G, Genco RJ. Update of the case definitions for						
4 5 6	437	population-based surveillance of periodontitis. J Periodontol. 2012;83:1449-1454.						
7 8 9	438	31. Schousboe JT, Debold CR. Reliability and accuracy of vertebral fracture assessment with						
10 11 12	439	densitometry compared to radiography in clinical practice. Osteoporos Int. 2006;17:281-289.						
13 14 15	440	32. Schousboe JT, Lewis JR, Kiel DP. Abdominal aortic calcification on dual-energy X-ray						
16 17 18	441	absorptiometry: Methods of assessment and clinical significance. <i>Bone</i> . 2017;104:91-100.						
19 20	442	33. Shah PD, Badner VM, Moss KL. Association between asthma and periodontitis in the US adult						
21 22 23	443	population: A population-based observational epidemiological study. J Clin Periodontol.						
23 24 25 26	444	2022;49:230-239.						
27 28	445	34. Chen W, Eisenberg R, Mowrey WB, et al. Association between dietary zinc intake and abdominal						
29 30 31	446	aortic calcification in US adults. Nephrol Dial Transplant. 2020;35:1171-1178.						
32 33 34	447	35. Whelton PK, Carey RM, Aronow WS, et al.2017						
35 36	448	ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention,						
37 38 39	449	detection, evaluation, and management of high blood pressure in adults: a report of the American						
40 41	450	College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am						
42 43 44	451	Coll Cardiol. 2018;71:e127–248.						
45 46	452	36. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group.						
47 48 40	453	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int.						
49 50 51	454	2021;100:S1-S276.						
52 53 54	455	37. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration						
55 56 57	456	rate. Ann Intern Med. 2009;150:604-612.						
58 59		For poor roview only http://bmienen.hmi.com/site/about/avidalines.yhtml 23						
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 25						

## BMJ Open

2 3	457	38. Stekhoven DJ, Bühlmann P. MissForestnon-parametric missing value imputation for mixed-type
4 5 6	458	data. Bioinformatics. 2012;28:112-118.
7 8 9	459	39. Sanz M, Marco Del Castillo A, Jepsen S, et al. Periodontitis and cardiovascular diseases: Consensus
10 11	460	report. J Clin Periodontol. 2020;47:268-288.
12 13 14	461	40. Tiensripojamarn N, Lertpimonchai A, Tavedhikul K, et al. Periodontitis is associated with
15 16 17	462	cardiovascular diseases: A 13-year study. J Clin Periodontol. 2021;48:348-356.
18 19 20	463	41. Paul O, Arora P, Mayer M, Chatterjee S. Inflammation in Periodontal Disease: Possible Link to
21 22 23	464	Vascular Disease. Front Physiol. 2021;11:609614.
24 25	465	42. Zhang J, Xie M, Huang X, et al. The Effects of Porphyromonas gingivalis on Atherosclerosis-
26 27 28	466	Related Cells. Front Immunol. 2021;12:766560.
29 30 31	467	43. Corredor Z, Suarez-Molina A, Fong C, Cifuentes-C L, Guauque-Olarte S. Presence of periodontal
32 33	468	pathogenic bacteria in blood of patients with coronary artery disease. Sci Rep. 2022;12:1241.
34 35 36	469	44. Li J, Deng J, Shang S, et al. Effect of Porphyromonas gingivalis lipopolysaccharide on calcification
37 38	470	of human umbilical artery smooth muscle cells co-cultured with human periodontal ligament cells. Exp
39 40 41 42	471	Ther Med. 2021;21:655.
43 44	472	45. Machado V, Botelho J, Escalda C, et al. Serum C-Reactive Protein and Periodontitis: A Systematic
45 46 47	473	Review and Meta-Analysis. Front Immunol. 2021;12:706432.
48 49 50	474	46. Andreu R, Santos-Del-Riego S, Payri F. Serum Inflammatory and Prooxidant Marker Levels in
51 52 53	475	Different Periodontal Disease Stages. Healthcare (Basel). 2021;9:1070.
54 55	476	47. Munafò MR, Tilling K, Taylor AE, Evans DM, Davey Smith G. Collider scope: when selection
56 57 58	477	bias can substantially influence observed associations. Int J Epidemiol. 2018;47:226-235.
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 24

2 3	478	48. Morelli T, Moss KL, Preisser JS, et al. Periodontal profile classes predict periodontal disease
4 5 6 7	479	progression and tooth loss. J Periodontol. 2018;89:148-156.
7 8 9 10	480	Figure legends
11	481	Figure 1. Flow chart of eligible National Health and Nutrition Examination Survey (NHANES)
$\begin{array}{c} 12\\ 13\\ 14\\ 15\\ 16\\ 17\\ 18\\ 19\\ 20\\ 22\\ 23\\ 24\\ 25\\ 26\\ 27\\ 28\\ 29\\ 30\\ 13\\ 23\\ 34\\ 35\\ 36\\ 37\\ 38\\ 90\\ 41\\ 42\\ 44\\ 46\\ 47\\ 48\\ 9\\ 51\\ 52\\ 34\\ 55\\ 56\\ 7\\ 58\end{array}$	482	participants included in this study.
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 25




Figure 1. Flow chart of eligible National Health and Nutrition Examination Survey (NHANES) participants included in this study.

655x679mm (72 x 72 DPI)

## **Supplementary Material**

TABLE 1 The numbers and percentages of missing covariate data

Covariate	Numbers	Percentages (%)
Education	1	0.05
Poverty-income ratio	176	8.19
Body mass index	6	0.28
Smoking status	2	0.09
Alcohol consumption status	97	4.51
Cardiovascular diseases	1	0.05
Chronic kidney disease	52	2.42
Albumin	58	2.70
Serum calcium	72	3.35
Serum phosphorus	59	2.75
Uric acid	60	2.79
Total 25-hydroxyvitamin D	49	2.28
Hemoglobin	38	1.77
Total cholesterol	53	2.47
High-density lipoprotein cholesterol	53	2.47
Triglycerides	60	2.79

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

**TABLE 2** General characteristics of included participants (n = 1,818) according to the periodontal status in the NHANES 2013–2014 (excluded participants with missing covariates).

Characters	Overall (n=1,818)	No Periodontitis (n=977)	Mild-Moderate periodontitisc (n=661)	Severe periodontitis (n=180)	P-val
Age, year	55.19±0.33	$54.01 \pm 0.46$	$57.70 \pm 0.57$	$55.36 \pm 0.69$	< 0.0
Gender					< 0.0
Male	50.34 (43.00-57.67)	45.25 (41.74-48.75)	57.01 (52.84-61.19)	69.00 (60.78-77.22)	
Female	49.66 (43.17-56.16)	54.75 (51.25-58.26)	42.99 (38.81-47.16)	31.00 (22.78-39.22)	
Race	· · · · · ·	· · · · ·	· · · · · ·	· · · · ·	< 0.0
Mexican American	7.64 (4.29-10.99)	5.37 (2.90-7.83)	12.37 (6.12-18.62)	8.40 (2.34-14.45)	
Non-Hispanic Black	9.81 (8.10-11.53)	7.07 (5.36-8.78)	12.69 (8.36-17.02)	23.04 (14.37-31.72)	
Non-Hispanic White	69.93 (55.21-84.66)	75.53 (70.47-80.58)	60.66 (49.90-71.41)	57.80 (45.71-69.90)	
Other Hispanic	4.87 (3.34-6.40)	4.10 (2.37-5.83)	6.45 (3.97-8.92)	5.27 (1.70-8.84)	
Other race or multi-racial	7.74 ( 6.20- 9.28)	7.94 (6.34- 9.54)	7.83 (4.98-10.68)	5.48 (2.78-8.18)	
Education	(((((((((((((((((((((((((((((((((((((((	(0.0 1 ) 10 1)	(100 (100 1000))		< 0.0
Less than hight school	13.49 (10.82-16.16)	7.91 ( 5.25-10.56)	20.34 (14.62-26.06)	36.09 (26.10-46.08)	0.0
Hight school	21.25 (16.88-25.62)	16.12 (12.81-19.42)	29.19 (23.88-34.51)	34.89 (27.67-42.12)	
Above hight school	65.26 (52.75-77.76)	75.98 (71.61-80.34)	50.47 (44.14-56.80)	29.02 (17.31-40.72)	
Poverty-income ratio	<u>(</u>	, 5.70 (71.01-00.34)	55.17 (11.14-50.00)	27.02 (17.31-10.72)	< 0.0
< 1.3	17.53 (12.79-22.26)	10.69 (7.03-14.35)	28.23 (21.62-34.84)	35.11 (21.93-48.30)	- 0.0
1.3-3.5	32.60 (28.53-36.67)	26.79 (22.77-30.80)	42.48 (37.54-47.42)	44.16 (33.74-54.59)	
> 3.5	49.88 (38.79-60.96)	62.52 (56.61-68.44)	29.29 (23.25-35.33)	20.73 (9.98-31.48)	
Insurance coverage	85.84 (72.59-99.10)	92.31 (89.14-95.48)	77.09 (73.42-80.77)	63.27 (55.48-71.07)	< 0.0
Body mass index (kg/m2)	05.0+(12.55-55.10)	72.51 (07.14-75.40)	(1.0) (13.42-00.77)	03.27 (33.40-71.07)	0.0
< 30	63.56 (53.32-73.81)	66.24 (62.27-70.22)	58.38 (52.44-64.31)	60.96 (51.39-70.54)	0.0
$\leq 30$ $\geq 30$					
	36.44 (31.69-41.18)	33.76 (29.78-37.73)	41.62 (35.69-47.56)	39.04 (29.46-48.61)	< 0.0
Smoking status Now	16.29 (13.83-18.75)	10 56 ( 7 05 12 16)	22 14 (18 08 26 10)	11 56 (31 80 51 22)	< 0.0
Former	( )	10.56 (7.95-13.16)	22.14 (18.08-26.19)	44.56 (34.80-54.33)	
Never	25.66 (20.34-30.98)	22.66 (19.38-25.94)	32.94 (26.12-39.75)	22.22 (12.52-31.92)	
	58.05 (49.27-66.83)	66.79 (62.21-71.36)	44.93 (39.88-49.98)	33.22 (22.02-44.41)	0.0
Alcohol consumption status	10 71 (7 52 12 00)	10 (1 (( 27 14 04)		7 42 (2 00 11 92)	0.0
Never	10.71 (7.52-13.90)	10.61 (6.27-14.94)	11.70 (9.07-14.33)	7.42 (3.00-11.83)	
Former	14.43 (11.55-17.31)	11.67 (9.23-14.11)	19.33 (16.24-22.41)	19.08 (13.23-24.92)	
Mild	40.15 (32.54-47.76)	43.22 (37.75-48.68)	35.28 (29.93-40.63)	32.53 (24.03-41.03)	
Moderate	18.73 (14.49-22.97)	19.72 (16.57-22.87)	17.18 (11.48-22.88)	16.25 (8.35-24.15)	
Heavy	15.98 (13.25-18.70)	14.79 (11.82-17.77)	16.51 (11.81-21.21)	24.73 (16.17-33.29)	<u> </u>
Cardiovascular diseases	7.82 (6.33-9.32)	6.24 (5.05- 7.44)	11.38 (8.50-14.26)	7.24 (2.99-11.48)	0.0
Hypertension	56.45 (49.84-63.06)	52.01 (47.49-56.52)	63.21 (58.69-67.74)	68.69 (63.15-74.24)	< 0.
Diabetes	14.17 (11.92-16.43)	10.97 (9.01-12.93)	21.37 (18.55-24.19)	12.97 (7.27-18.67)	< 0.
Chronic kidney disease	14.93 (12.73-17.13)	12.57 (10.40-14.75)	19.74 (16.90-22.59)	16.15 (10.83-21.47)	< 0.
AAC-8 score					0.0
< 3	94.75 (82.27-107.22)	96.32 (94.70-97.94)	91.82 (89.49-94.15)	92.69 (88.05-97.32)	
$\geq$ 3	5.25 ( 3.65- 6.86)	3.68 (2.06- 5.30)	8.18 (5.85-10.51)	7.31 (2.68-11.95)	
AAC-24 score					0.0
0	75.38 (64.00-86.75)	77.23 (73.37-81.09)	73.27 (67.34-79.21)	67.15 (58.31-76.00)	
1-6	19.79 (15.77-23.82)	19.62 (15.94-23.31)	18.85 (14.06-23.64)	25.48 (17.29-33.67)	
> 6	4.83 (3.85-5.81)	3.15 (2.14-4.16)	7.88 (5.61-10.15)	7.37 (2.91-11.83)	
Laboratory measurements					
Albumin (g/dL)	$4.27 \pm 0.01$	$4.29 \pm 0.02$	$4.22 \pm 0.02$	$4.20 \pm 0.03$	0.0
Serum calcium (mg/dL)	$9.45 \pm 0.01$	$9.45 \pm 0.01$	$9.43 \pm 0.02$	$9.47 \pm 0.03$	0.5
Serum phosphorus (mg/dL)	$3.79 \pm 0.02$	$3.81 \pm 0.03$	$3.74 \pm 0.02$	$3.77 \pm 0.03$	0.0
Uric acid (mg/dL)	$5.37 \pm 0.02$	$5.29 \pm 0.04$	$5.54 \pm 0.10$	$5.45 \pm 0.14$	0.1
Total 25-hydroxyvitamin D	$3.37 \pm 0.04$ $73.21 \pm 1.48$	$5.29 \pm 0.04$ 76.57 ± 1.85	$5.34 \pm 0.10$ $68.88 \pm 1.87$	$5.43 \pm 0.14$ $60.62 \pm 2.46$	< 0.12
(nmol/L)					
Hemoglobin (g/dL)	$14.21 \pm 0.04$	$14.17 \pm 0.04$	$14.23 \pm 0.09$	$14.44 \pm 0.12$	0.1
Total cholesterol (mg/dL)	$195.97 \pm 1.04$	$195.69 \pm 1.29$	$196.00 \pm 1.97$	$198.53 \pm 3.98$	0.8
High-density lipoprotein cholesterol (mg/dL)	$54.62 \pm 0.70$	$56.58 \pm 0.85$	$51.33 \pm 0.75$	$50.60 \pm 1.43$	< 0.0
Triglycerides (mg/dL)	$160.21 \pm 3.40$	$152.06 \pm 4.25$	$174.33 \pm 4.71$	175.34±16.35	0.0

BMJ Open: first published as 10.1136/bmjopen-2022-068931 on 15 March 2023. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright.

Values indicate the weighted mean ± SD or weighted % (95% confidence interval). P-values are weighted. AAC, abdominal aortic calcification

**TABLE 3** Weighted multiple logistic regression coefficients (ORs) and 95% confidence intervals for the association between periodontal status with AAC group: The United States, 2013 to 2014 (exclude participants with missing covariates)

	Case/participants	Model 1	Model 2	Model 3
	1 1	OR (95% CI), P- value	OR (95% CI), P- value	OR (95% CI), P- value
AAC-8 score ≥ 3 points versus	AAC-8 score < 3 poi	ints		
No periodontitis	44/977	Reference	Reference	Reference
Mild-moderate periodontitis	57/661	1.72(0.84,3.54)	1.53(0.81,2.88)	1.56(0.83,2.92)
wind-moderate periodontitis	577001	p=0.116	p=0.171	p=0.153
Severe periodontitis	15/180	2.44(0.96,6.21)	1.80(0.81,4.00)	1.80(0.77,4.22)
*		p=0.059	p=0.137	p=0.160
Mild-moderate AAC versus no				
No periodontitis	224/939	Reference	Reference	Reference
Mild-moderate periodontitis	144/607	0.87(0.58,1.31)	0.71(0.50,1.02)	0.69(0.49,0.97)
fina moderate periodonities	111/00/	p=0.439	p=0.060	p=0.033
Severe periodontitis	50/164	1.52(0.78,2.96)	1.06(0.49,2.30)	0.99(0.46,2.10)
Severe periodolititis	50/101	p=0.181	p=0.869	p=0.972
Severe AAC versus no AAC				
No periodontitis	38/784	Reference	Reference	Reference
Mild-moderate periodontitis	54/538	2.11(1.10, 4.05)	1.89(1.02, 3.50)	1.89(1.01, 3.56)
tind modelate periodonities	5 11 5 5 6	p=0.030	p=0.044	p=0.048
Severe periodontitis	16/139	5.22(1.85,14.76)	2.81(1.06, 7.42)	2.73(0.92, 8.13)
1		p=0.007	p=0.038	p=0.068
Severe AAC versus mild–mode	erate AAC			
No periodontitis	38/231	Reference	Reference	Reference
Mild-moderate periodontitis	54/177	2.20(1.20,4.04)	1.82(0.98,3.39)	1.87(0.96, 3.66)
wind-moderate periodolititis	JT/1//	p=0.018	p=0.059	p=0.065
Severe periodontitis	16/57	2.41(0.79,7.29)	1.85(0.78,4.38)	1.85(0.75, 4.60)
Severe periodolititis	10/37	p=0.103	p=0.147	p=0.168

Model 1 was adjusted for age, sex, and race; Model 2 was adjusted for the parameters in Model 1 plus insurance, education level, smoking status, alcohol consumption status, PIR, BMI, diabetes, hypertension, CVD and CKD; and Model 3 was adjusted for the parameters in Model 2 plus albumin, serum calcium, serum phosphorus, uric acid, total 25-hydroxyvitamin D, hemoglobin, TC, HDL-C, and TGs. No AAC, mild–moderate AAC and Severe AAC were defined by AAC-24 score. AAC: abdominal aortic calcification.

**TABLE 4** Weighted multiple logistic regression coefficients (ORs) and 95% confidence intervals for the association between periodontal status (exclude participants with mild periodontitis) with AAC group: The United States, 2013 to 2014

	Case/participants	Model 1	Model 2	Model 3
		OR (95% CI), P- value	OR (95% CI), P- value	OR (95% CI), P- value
AAC-8 score ≥ 3 points versus	AAC-8 score < 3 poi	ints		
No periodontitis	34/1142	Reference	Reference	Reference
Moderate periodontitis	53/773	1.94(0.86,4.40) P=0.096	1.68(0.82,3.46) P=0.147	1.73(0.87,3.42) P=0.109
Severe periodontitis	14/220	3.12(1.17,8.36) P=0.029	2.44(1.02,6.00) P=0.046	2.44(1.01,6.05) P=0.048
Mild–moderate AAC versus n	o AAC			
No periodontitis	224/1102	Reference	Reference	Reference
Moderate periodontitis	141/711	0.90(0.57,1.41) P=0.587	0.75(0.52,1.09) P=0.121	0.72(0.50,1.03) P=0.069
Severe periodontitis	50/200	1.46(0.80,2.68) P=0.184	1.05(0.52,2.11) P=0.881	0.96(0.48,1.94) P=0.906
Severe AAC versus no AAC				
No periodontitis	40/918	Reference	Reference	Reference
Moderate periodontitis	62/632	2.37(1.07, 5.22) P=0.036	1.97(0.96,4.06) P=0.063	2.03(1.02,4.03) P=0.044
Severe periodontitis	20/170	6.02(2.44,14.86) P=0.002	3.49(1.53,7.97) P=0.006	3.48(1.42,8.54) P=0.010
Severe AAC versus mild-mod	erate AAC			
No periodontitis	40/264	Reference	Reference	Reference
Moderate periodontitis	62/203	2.47(1.23,4.96) P=0.018	2.10(1.08,4.07) P=0.031	2.17(1.09, 4.32) P=0.030
Severe periodontitis	20/70	3.10(1.15,8.32) P=0.030	2.76(1.16,6.57) P=0.025	2.75(1.14, 6.63) P=0.027

Model 1 was adjusted for age, sex, and race; Model 2 was adjusted for the parameters in Model 1 plus insurance, education level, smoking status, alcohol consumption status, PIR, BMI, diabetes, hypertension, CVD and CKD; and Model 3 was adjusted for the parameters in Model 2 plus albumin, serum calcium, serum phosphorus, uric acid, total 25-hydroxyvitamin D, hemoglobin, TC, HDL-C, and TGs. No AAC, mild–moderate AAC and Severe AAC were defined by AAC-24 score. AAC: abdominal aortic calcification.

BMJ Open: first published as 10.1136/bmjopen-2022-068931 on 15 March 2023. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright

**TABLE 5** Weighted multiple logistic regression coefficients (ORs) and 95% confidence intervals for the association between periodontal status with AAC group: The United States, 2013 to 2014 (exclude participants with cardiovascular diseases)

	Case/participants	Model 1 OR (95% CI), P- value	Model 2 OR (95% CI), P- value	Model 3 OR (95% CI), P- value
AAC-8 score $\geq$ 3 points versus	AAC-8 score < 3 po	× //		
No periodontitis	34/1066	Reference	Reference	Reference
Mild–moderate periodontitis	53/692	2.25(0.98,5.17) P= 0.054	1.90(0.95,3.81) P=0.067	1.95(1.02,3.73) P=0.044
Severe periodontitis	14/202	3.27(1.26,8.48) P=0.022	2.18(0.88,5.45) P=0.088	2.14(0.86,5.35) P=0.096
Mild-moderate AAC versus no	AAC			
No periodontitis	208/1038	Reference	Reference	Reference
Mild–moderate periodontitis	118/639	0.83(0.52,1.32) P=0.371	0.68(0.47,0.99) P=0.049	0.65(0.45,0.94) P=0.026
Severe periodontitis	44/187	1.33(0.70,2.51) P=0.330	0.90(0.41,1.95) P=0.774	0.83(0.38,1.81) P=0.618
Severe AAC versus no AAC				
No periodontitis	28/858	Reference	Reference	Reference
Mild–moderate periodontitis	53/574	3.17(1.61, 6.26) P=0.005	2.62(1.44, 4.76) P=0.004	2.71(1.49, 4.93) P=0.003
Severe periodontitis	15/158	6.00(2.47,14.57) P=0.002	3.00(1.31, 6.87) P=0.013	2.89(1.13, 7.40) P=0.029
Severe AAC versus mild-mode	rate AAC			
No periodontitis	28/236	Reference	Reference	Reference
Mild-moderate periodontitis	53/171	3.17(1.73, 5.80) P=0.003	2.99(1.68, 5.32) P=0.001	3.16(1.75, 5.69) P<0.001
Severe periodontitis	15/59	3.79(1.38,10.43) P=0.017	3.82(1.42,10.27) P=0.011	3.75(1.32,10.60) P=0.016

Model 1 was adjusted for age, sex, and race; Model 2 was adjusted for the parameters in Model 1 plus insurance, education level, smoking status, alcohol consumption status, PIR, BMI, diabetes, hypertension and CKD; and Model 3 was adjusted for the parameters in Model 2 plus albumin, serum calcium, serum phosphorus, uric acid, total 25-hydroxyvitamin D, hemoglobin, TC, HDL-C, and TGs. No AAC, mild-moderate AAC and Severe AAC were defined by AAC-24 score. AAC: abdominal aortic calcification.

BMJ Open: first published as 10.1136/bmjopen-2022-068931 on 15 March 2023. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright

3 4

STROBE Statement-	-Checklist of items the	at should be included in reports of <i>cross-sectional studies</i>	/bmjopen-2022-068
	Item No	Recommendation	Page number and Line number
Title and abstract	1 ✓ title+abstract	( <i>a</i> ) Indicate the study's design with a commonly used term in the title or the abstract	Page 1-2 9 Line 2-4; 15-36 5
		( <i>b</i> ) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 1-2 Arcs Line 2-4; 15-36
Introduction			2023
Background/rationale	$2\checkmark$ introduction	Explain the scientific background and rationale for the investigation being reported	Page 3-4 D Line 47-73 <u>5</u>
Objectives	$3\checkmark$ introduction	State specific objectives, including any prespecified hypotheses	Page 4 A Line 74-83
Methods			
Study design	4 ✓ data source	Present key elements of study design early in the paper	Page 5
Setting	5 ✓ data source	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 5 9 Line 86-105
Participants	6 ✓ data source	( <i>a</i> ) Give the eligibility criteria, and the sources and methods of selection of participants	Page 5
Variables	<ul> <li>7 ✓ definitions of periodontitis;</li> <li>abdominal aortic calcification</li> <li>outcomes; covariates</li> </ul>	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 5-8 09 Line 106-162 April 20, 2024
Data sources/ measurement	8* ✓ definitions of periodontitis; abdominal aortic calcification outcomes; covariates	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 5-8 Line 106-162 Potect
Bias	9 ✓ statistical analysis	Describe any efforts to address potential sources of bias	Page 8-9 ट्
Study size	10 ✓ data source;	Explain how the study size was arrived at	Line 163-191 8 Page 5 5

	BMJ Open		DTI. Pag
figure 1;		Line 86-105	/b mjo pen- 20222- -06 89 331
11 ✓ statistical analysis	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 8-9 Line 163-191	68 93 1 on
12 ✓ statistical analysis ✓ statistical analysis	<ul> <li>(a) Describe all statistical methods, including those used to control for confounding</li> <li>(b) Describe any methods used to examine subgroups and</li> </ul>	Page 8-9 Line 163-191 Page 8-9	15 March 2023.
<ul> <li>✓ statistical analysis</li> <li>✓ statistical analysis</li> </ul>	(c) Explain how missing data were addressed	Page 8-9 Line 163-191	Downloaded
✓ statistical analysis	<ul> <li>(d) If applicable, describe analytical methods taking account of sampling strategy</li> <li>(e) Describe any sensitivity analyses</li> </ul>	Page 8-9 Line 163-191 Page 8-9 Line 163-191	ded from http://
13* ✓ data source; figure 1 ✓ data source; figure	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 5 Line 86-105	open.bmj.com/
1;supplementary table1	(b) Give reasons for non-participation at each stage	Page 5 Line 86-105	on April
✓figure 1	(c) Consider use of a flow diagram	-	20,
14* ✓ table 1	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 9-11 Line 196-211	2024 by gu
✓ supplementary table1	(b) Indicate number of participants with missing data for each variable of interest	-	est. Prot
15* ✓ Table 1 to 4	Report numbers of outcome events or summary measures	-	
16 ✓ table 2; table 3; Table 4;	( <i>a</i> ) Give unadjusted estimates and, if applicable, confounder- adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and	-	tected by copyright.
-	analysis 12 $\checkmark$ statistical analysis $\checkmark$ statistical analysis $\checkmark$ statistical analysis $\uparrow$	figure 1;         11 ✓ statistical analysis       Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why         12 ✓ statistical analysis       (a) Describe all statistical methods, including those used to control for confounding         ✓ statistical analysis       (b) Describe any methods used to examine subgroups and interactions         ✓ statistical analysis       (c) Explain how missing data were addressed         ✓ statistical analysis       (d) If applicable, describe analytical methods taking account of sampling strategy         (g) Describe any sensitivity analyses       (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility,         ✓ data source; figure 1       (a) Report numbers of non-participation at each stage         1;supplementary       (b) Give reasons for non-participation at each stage         4ble1       (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders         ✓ supplementary       (b) Indicate number of participants with missing data for each variable of interest         15* ✓ Table 1 to 4       Report numbers of outcome events or summary measures         16 ✓ table 2; table 3;       (a) Give unadjusted estimates and, if applicable, confounder-	figure 1;Line 86-10511 $\checkmark$ statistical analysisExplain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and whyPage 8-9 Line 163-191 and why12 $\checkmark$ statistical analysis(a) Describe all statistical methods, including those used to control for confoundingPage 8-9 Line 163-191 Line 163-191 $\checkmark$ statistical analysis(b) Describe any methods used to examine subgroups and interactionsPage 8-9 Line 163-191 $\checkmark$ statistical analysis(c) Explain how missing data were addressedPage 8-9 Line 163-191 $\checkmark$ statistical analysis(c) Explain how missing data were addressedPage 8-9 Line 163-191 $\checkmark$ statistical analysis(d) If applicable, describe analytical methods taking account of sampling strategyPage 8-9 Line 163-191 $\checkmark$ statistical analysis(d) If applicable, describe analytical methods taking account of gene 8-9 sampling strategyPage 8-9 Line 163-191 $(d)$ If applicable, describe any sensitivity analysesPage 8-9 Line 163-191Line 163-191 $(e)$ Describe any sensitivity analysesPage 5 Line 163-191Line 86-105 $\checkmark$ figure 1(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, and analysedLine 86-105 $\checkmark$ figure 1(e) Consider use of a flow diagram- $14* \checkmark$ table 1(a) Give characteristics of study participants (eg demographic, confoundersPage 9-11 Line 166-105 $\checkmark$ supplementary table1(b) Indicate number of participants with missing data for each variabl

#### BMJ Open

f 34		BMJ Open		/bmjopen-2022-068931
				n-2022
		why they were included		2-06
	✓ covariates	(b) Report category boundaries when continuous variables were	Page 7-8	893
		categorized	Line 133-162	
		(c) If relevant, consider translating estimates of relative risk	-	<b>1</b> 5
	× this study does	into absolute risk for a meaningful time period		March
	not involve			
Other analyses	$17 \checkmark \text{results}$	Report other analyses done-eg analyses of subgroups and	Page 13-15	2023.
		interactions, and sensitivity analyses	Line 242-270	.α. 
Discussion				О Wr
Key results	$18 \checkmark \text{discussion} - 1^{\text{nd}}$	Summarise key results with reference to study objectives	Page 15	lloaded
	paragraph	<b>b</b>	Line 272-286	ded
Limitations	$19 \checkmark discussion - 4^{th}$	Discuss limitations of the study, taking into account sources of	Page 17-18	from
	paragraph	potential bias or imprecision. Discuss both direction and	Line 329-345	
		magnitude of any potential bias		http://bmjopen
Interpretation	$20 \checkmark \text{discussion} - 2^{\text{th}}$ -	Give a cautious overall interpretation of results considering	Page 15-17	omje
	3 <sup>th</sup> paragraphs	objectives, limitations, multiplicity of analyses, results from	Line 287-328	per
		similar studies, and other relevant evidence		1. br
Generalisability	21 $\checkmark$ discussion – 4 <sup>th</sup>	Discuss the generalisability (external validity) of the study	Page 17-18	ij.com/
		results	Line 329-345	
Other information				on A
Funding	22 🗸	Give the source of funding and the role of the funders for the	Page 19	April
		present study and, if applicable, for the original study on which	Line 362-363	20,
		the present article is based		2024

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.stopbe-statement.org.

copyright.

## Unraveling the link between periodontitis and abdominal aortic calcification in the U.S. adult population: A crosssectional study based on the NHANES 2013-2014

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-068931.R1
Article Type:	Original research
Date Submitted by the Author:	24-Jan-2023
Complete List of Authors:	Kadier, Kaisaierjiang; Xinjiang Medical University Affiliated First Hospital, Cardiology Abulizi, Anniwaer; Xinjiang Medical University Affiliated First Hospital Ainiwaer, Aikeliyaer; Xinjiang Medical University Affiliated First Hospital Rehemuding, Rena; Xinjiang Medical University Affiliated First Hospital, Department of Cardiology Ma, Xiang; Xinjiang Medical University Affiliated First Hospital, Heart Center Ma, Yi-Tong ; Xinjiang Medical University Affiliated First Hospital
<b>Primary Subject Heading</b> :	Cardiovascular medicine
Secondary Subject Heading:	Dentistry and oral medicine, Epidemiology, Public health
Keywords:	Vascular medicine < INTERNAL MEDICINE, PUBLIC HEALTH, ORAL MEDICINE, EPIDEMIOLOGY, Cardiac Epidemiology < CARDIOLOGY

SCHOLARONE<sup>™</sup> Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

R. O.

BMJ Open: first published as 10.1136/bmjopen-2022-068931 on 15 March 2023. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright.

1 2 3 4 5	1	The title page
6 7 8 9	2	Unraveling the link between periodontitis and abdominal aortic
9 10 11 12	3	calcification in the U.S. adult population: A cross-sectional study based
13 14 15	4	on the NHANES 2013-2014
16 17 18	5	Kaisaierjiang Kadier*, Anniwaer Abulizi*, Aikeliyaer Ainiwaer*, Rena Rehemuding, Xiang
19 20 21	6	Ma, and Yi-Tong Ma
22 23 24	7	Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
25 26 27 28	8	Correspondence:
29 30	9	Xiang Ma, Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University,
31 32 33	10	Xinyi Road No. 393, Urumqi 830054, China. Email: maxiangxj@yeah.net
34 35 36	11	Yi-Tong Ma, Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University,
37 38 39	12	Xinyi Road No. 393, Urumqi 830054, China. Email: myt_xj@sina.com
40 41 42	13	Equal contributions: *These authors have contributed equally to this work and share first authorship
43 44 45 46	14	Word count: 3,603; Number of figures: 1; Number of tables: 4; Number of references: 48.
47 48 49 50	15	Abstract
50 51 52	16	Objective: We aimed to explore the association between periodontitis and abdominal aortic
53 54 55	17	calcification (AAC) among a nationally representative sample of U.S. adults.
56 57 58	18	Design: Cross- sectional study.
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 1

#### **BMJ** Open

Setting: The National Health and Nutrition Examination Survey (2013–2014). Participants: A total of 2,149 participants aged 40 years or older who have complete information for periodontitis and AAC assessment test were included in this study. Primary and secondary outcome measures: AAC scores can be accurately identified on lateral spine images obtained by DXA, and both the AAC-24 and AAC-8 semiguantitative scoring tools were used for AAC evaluation. Linear regression analysis was used to investigate the relationship between periodontitis and the AAC-8 and AAC-24 scores. Multivariate logistic regression models and reported odds ratios (ORs) were used to examine the relationship between periodontitis and AAC. **Results:** The prevalence of severe periodontitis combined with severe AAC was 8.49%-8.54%. According to the AAC-8 and AAC-24 score classifications, patients with severe periodontitis had higher odds of severe AAC [AAC-8 score  $\geq$  3: (OR: 2.53; 95% CI 1.04, 6.17) and AAC-24 score >6: (OR: 3.60; 95% CI 1.48, 8.78)]. A positive association between mild-moderate periodontitis and severe AAC was found only when the AAC-24 score was applied (OR: 2.25; 95% CI 1.24, 4.06). In the subgroup analyses, the likelihood ratio test showed no multiplicative interaction (all P for interaction > 0.05). Conclusions: The findings showed that periodontitis is associated with an increased risk of severe 

AAC in the U.S. population aged 40 years and older; this requires further large-scale prospective studies for confirmation.

37 Strengths and limitations of this study

A complex, multistage probability sampling approach was used to obtain a representative sample of
 individual composition to investigate the total national population.

2. Our study fully considered socioeconomic status, behavioral factors and medical history of theparticipants and controlled for a wide range of confounders.

42 3. Periodontitis and abdominal aortic calcification were defined based on objective clinical data43 collected by calibrated professionals.

44 4. Given the cross-sectional design of the NHANES, it is difficult for us to determine causality, and
45 further large-scale prospective studies are needed.

5. Because of the sample size, we were not able to include the new periodontal profile class (PPC)
system to precisely classify periodontal disease.

# Text

#### **1.** Introduction

Periodontitis has become a global public health challenge and imposes serious burdens on society and health services. There have been approximately 1.1 billion prevalent cases of severe periodontitis worldwide over the past 30 years, an increase of 8.44% in age-standardized prevalence<sup>1</sup>. Forty-six percent of American adults aged 30 years and older have periodontitis, 8.9% of whom have severe periodontitis, which is positively associated with increasing age<sup>2</sup>. Periodontitis can affect the risk of systemic diseases, including cardiovascular disease (CVD)<sup>3-4</sup>, diabetes<sup>5</sup>, and chronic kidney disease (CKD)<sup>6</sup>, through mechanisms such as periodontal microbial damage and inflammatory cascades, and this relationship may be causal and bidirectional. Deaths due to all causes and cause-specific causes are associated with periodontitis and its sequelae<sup>7</sup>. As part of its strategy, the Centers for Disease Control and Prevention (CDC) is supporting and improving periodontal disease surveillance<sup>8</sup>.

#### **BMJ** Open

The abdominal aorta is considered to valuable in observing early atherosclerotic calcification<sup>9</sup>, and its degree of calcification is closely related to the prevalence of and mortality due to  $CVD^{10}$ . Abdominal aortic calcification (AAC) is characterized by metabolic disorders involving minerals, such as calcium and phosphorus, and abnormal deposition in the vascular wall, which is common in patients with chronic disease<sup>11-12</sup>. Some epidemiological evidence suggests that periodontitis is associated with arterial calcification at multiple sites. A Chinese cohort study showed that periodontitis increased the risk of aortic calcification and was more pronounced in men and younger participants than in women and older participants<sup>13</sup>. In addition, a cross-sectional study and meta-analysis suggested that periodontitis was associated with carotid calcification<sup>14-15</sup>, and there was radiographic evidence suggesting the possible involvement of intracranial carotid calcification<sup>16</sup>. However, other cohort studies reported inconsistent conclusions<sup>17-18</sup>. In recent years, vascular calcification, including soft tissue calcification, has been recognized as an active process regulated by multiple molecular signaling pathways in response to chronic inflammatory stimuli<sup>19</sup>. Previous animal studies demonstrated that periodontitis and vascular calcification promoted each other<sup>20</sup>, and the mechanisms involved were gradually revealed in subsequent studies<sup>21-24</sup>. 

An assessment of the utility of the AAC score in a 25-year cohort study of 617 Framingham Heart Study participants was conducted by Kauppila et al. using lateral lumbar radiography as the AAC grading tool (AAC score)<sup>25</sup>. Based on the AAC score, it is possible to assess subclinical vascular disease at a low cost, with predictive value for cardiovascular events and mortality independent of coronary calcification<sup>26</sup>. Therefore, using abdominal aortic calcification data obtained from dual-energy X-ray absorptiometry (DXA) in the 2013–2014 National Health and Nutrition Examination Survey (NHANES), the aim of this study was to investigate the relationship between periodontitis and AAC and propose new ideas for the prevention and management of AAC in clinical practice. We hypothesized that periodontitis would be associated with an increased prevalence of AAC. 

BMJ Open: first published as 10.1136/bmjopen-2022-068931 on 15 March 2023. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright

#### 2. Materials and methods

2.1. Data source

The current cross-sectional study analyzed data from individuals who participated in the 2013 to 2014 NHANES, which was performed by the National Center for Health Statistics (NCHS) at the CDC. The NHANES 2013-2014 was a cross-sectional, nationally representative survey of the U.S. noninstitutionalized civilian population designed to examine demographic, socioeconomic, health, and nutritional information. To ensure a representative sample, complex multistage sampling was used to collect data, and strata were determined based on geographic location and population proportions<sup>27</sup>.

The NHANES 2013-2014 was the only cycle that also performed examinations for periodontitis and abdominal aortic calcification. Participants  $\geq 40$  years of age who received a full-mouth periodontal examination and participated in lateral DXA scans of the thoraco-lumbar spine were included in this study. In the 2013-2014 cycle of the NHANES, 10,175 participants completed the survey. However, in this study, individuals aged < 40 years without complete information about periodontitis and abdominal aortic calcification were excluded (N = 7,741). Additionally, cancer participants (N = 285) were excluded from the analysis. Ultimately, 2,149 participants were included in the analysis (Figure 1). All participants provided written informed consent to participate in NHANES, and the NCHS Research Ethics Review Board approved the protocol (NCHS IRB/ERB Protocol Number: Continuation of Protocol #2011-17). The study was designed according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for reporting cross-sectional studies<sup>28</sup>, and all procedures were performed in accordance with the principles of the Helsinki Declaration of 1975.

2.2. Definitions of periodontitis

#### **BMJ** Open

Oral health examinations were performed by dental examiners who were licensed dentists in at least one state in the U.S. During oral health assessments, a portable dental chair, lights, and compressed air were provided in a mobile examination center (MEC). All dental examiners received standardized training and collected reliable statistical data to objectively assess examiner agreement<sup>29</sup>.

Six measurement points were selected for periodontal examinations (mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual) for all teeth, with the exception of third molars. Indicators of periodontitis included probing depth (PD) and clinical attachment loss (AL), which are important bases for the CDC/AAP classification/case definition<sup>30</sup>. Accordingly, periodontitis was divided into mild periodontitis, moderate periodontitis and severe periodontitis, No periodontitis was defined as no evidence of mild, moderate, or severe periodontitis. Because there were few data from those with mild periodontitis, mild periodontitis and moderate periodontitis were combined for analysis in our study. 

## 2.3. Abdominal aortic calcification outcomes

AAC can be accurately identified on lateral spine images obtained by DXA and shows good sensitivity and specificity at lower radiation doses<sup>31-32</sup>. Those < 40 years old, pregnant, weighing over 450 pounds, or ingesting barium within the last week were ineligible for DXA scans in this study. Both the AAC-24 and AAC-8 semiquantitative scoring tools were used for AAC evaluation<sup>25</sup>. An assessment of the length of anterior and posterior aortic wall calcification anterior to the L1 to L4 vertebral bodies was made using the AAC-8 score, and participants with a score of three or more were considered to be at high risk for AAC. Using the L1-L4 region as a reference, the anterior and posterior aortic walls are divided into four segments to calculate the AAC-24 score. Depending on the degree of calcification, each vertebral body can receive a score from 0 to 6, with a total possible score of 0 to 24; this allows a more precise assessment of abdominal aortic calcification. We categorized AAC-24 scores 

129 into three groups: no calcification (AAC-24 score =0), mild to moderate calcification ( $6 \ge AAC-24$ 130 score > 0) and severe calcification (AAC-24 score >6).

Based on previous studies, we considered some confounding factors potentially associated with periodontitis and AAC in our analysis, including socioeconomic factors, behavioral factors, body mass index (BMI), medical history, and laboratory measurements<sup>33-34</sup>.

Information about socioeconomic factors was obtained during the home interview. The poverty income ratio (PIR) was stratified into <1.3, 1.3-3.5, and >3.5, as recorded in the original survey. Behavioral factors were obtained from self-reports. A never smoker is an individual who has never smoked more than 100 cigarettes in their lifetime. Former smokers were defined as those who smoked more than 100 cigarettes in their lifetime and had guit smoking, and smokers have to smoke at least 100 cigarettes in their lifetime and smoke some days or every day to qualify as current smokers. The status of alcohol consumption was categorised as never (never drank greater than or equal to 12 drinks in their lifetime), former (greater than or equal to 12 drinks in 1 year and did not drink last year, or did not drink last year but drank  $\geq 12$  drinks in their lifetime), current mild ( $\leq 1$  drink/d for female or  $\leq 2 \operatorname{drink/d}$  for male on average over the past year), current moderate (2 drink/d for female or 3 drink/d for male on average over the past year), current heavy drinkers (>3 drink/d for female or  $\geq$ 4 drink/d for male on average over the past year). BMI was measured at a MEC using standard protocols and stratified into  $\geq$ 30 and <30. 

Those participants who self-reported heart failure, angina, coronary heart disease, heart attack, or stroke diagnosed by a physician were classified as having CVD. The definition of hypertension was a diagnosis by a healthcare professional, an average blood pressure of  $\geq 130/80$  mmHg or using hypertension medications<sup>35</sup>. Diabetes was defined as a diagnosis made by a physician or

#### **BMJ** Open

other healthcare professional, HbA1c (%) >6.5, random blood glucose (mmol/l)  $\geq 11.1$ , or use of diabetes medication or insulin. As defined by the International Renal Association, chronic kidney disease is characterized by an estimated glomerular filtration rate <60 mL/min/1.73 m<sup>2</sup> or a urine albumin-creatinine ratio of at least 30<sup>36</sup>. Based on serum creatinine, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was used to estimate the glomerular filtration rate<sup>37</sup>. Laboratory data were obtained from participant serum samples that were processed in the Collaborative Laboratory Services, Ottumwa, Iowa, for analysis. Detailed instructions regarding specimen collection and processing are documented in the NHANES Laboratory Procedures Manual, and quality control was in accordance with standard procedures. 

#### **2.5. Statistical analysis**

A weight is assigned to the NHANES to compensate for the complex survey design, survey nonresponses, and poststratification adjustment to match the total U.S. population. All results of this study were weighted by 2-year MEC weights. In accordance with the CDC/AAP classification of periodontitis, descriptive statistics were calculated to describe the characteristics of the participants. Continuous variables are presented as the weighted mean  $\pm$  standard deviation (SD) and were compared using a one-way ANOVA, while categorical variables were compared using the Rao-Scott chi-square test and are presented as weighted percentages (95% confidence interval, 95% CI). Linear regression was used to evaluate the association of the AAC-8 score and AAC-24 score as dependent variables with periodontitis with varying degrees of severity as independent variables. Beta coefficients and 95% CIs were calculated. Multivariate logistic regression analysis was performed to evaluate the correlation between periodontitis with varying degrees of severity and AAC with varying degrees of severity using odds ratios (ORs) and 95% CIs. Model 1 was adjusted for age, sex, and race; Model 2 was adjusted for the parameters in Model 1 plus insurance, education level, smoking status, alcohol consumption status, PIR, BMI, diabetes, hypertension, CVD and CKD; and Model 3 was adjusted for the parameters in 

BMJ Open: first published as 10.1136/bmjopen-2022-068931 on 15 March 2023. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright

Model 2 plus albumin, serum calcium, serum phosphorus, uric acid, total 25-hydroxyvitamin D, hemoglobin, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TGs). Subgroup analysis stratified by age, sex, CVD, hypertension, diabetes, and CKD was also conducted using stratified multivariate regression analysis, and multiplicative interactions were assessed using likelihood ratio tests.

In this study, we used the MissForest<sup>38</sup> package in R software to address missing covariates. The algorithm can address categorical and continuous variables and shows superior performance. The numbers and percentages of missing covariate data are shown in Supplementary Material Table 1. Sensitivity analyses were performed as followed: (1) only participants with complete data were included, and participants with missing covariates were excluded; (2) mild and moderate periodontitis were not combined for analysis, and mild periodontitis was excluded; and (3) participants with CVD were excluded. R software (version 4.1.3) was used for all statistical analyses. It was considered statistically significant if the P value was less than 0.05 for all statistical tests of two-tailed. 

## 2.6. Patient and public involvement

Patients or the public were not involved in the design, or conduct, or reporting, or disseminationplans of our research.

**3.** Results

Descriptive statistics of our study participants by periodontitis status according to the CDC/AAP case definitions are presented in Table 1. The study included 2,149 participants, representing 86,199,511 noninstitutionalized adults (40 years and older) in the U.S. Overall, participants had a mean age±SD of  $54.96 \pm 0.32$  years; 50.46% (44.32, 56.60) were female, and 68.14% (54.20, 82.08) were non-Hispanic white. The prevalence of mild-moderate periodontitis was 29.93 (25.36, 34.51) and that of severe periodontitis was 6.77 (5.40, 8.13). Periodontitis was more prevalent in older individuals,

# BMJ Open

203 204 205 206	diabetes, hypertension, participants without per TABLE 1 General character NHANES 2013–2014.	riodontitis (all p <	0.05).		ľ	
204 205	participants without per TABLE 1 General character NHANES 2013–2014.	riodontitis (all p < eristics of included p	0.05). participants (n = 2,1 No Periodontitis	49) according to th Mild-Moderate	ne periodontal statu	is in the
204 205	participants without per TABLE 1 General character	riodontitis (all p <	0.05).		ľ	
204 205	participants without per TABLE 1 General character	riodontitis (all p <	0.05).		ľ	
	, <b>, , ,</b> , , , , , , , , , , , , , , ,	, , ,	5 5	amin D, TGs, an	d HDL-C compare	ed with
	, <b>, , ,</b> , , , , , , , , , , , , , , ,	, , ,	5 5	amin D, TGs, and	d HDL-C compare	ed with
203	diabetes, hypertension,	CKD, albumin, to	tal 25-hydroxyvit	amin D, TGs, and	d HDL-C compare	ed with
				· D TO		1 .1
202	In addition, we also fou	nd significant diffe	erences in smoking	g status, alcohol c	onsumption status	, CVD,
201	AAC and severe AAC	was significantly h	igher in participar	nts with periodont	itis than in those w	vithout.
200	than in their counterpar	rts and showed dif	ferences among r	aces. The prevale	ence of mild to m	oderate
199	males, those with a low	educational level,	those with a low F	PIR, and those wit	h low insurance co	overage
	200 201	200 than in their counterpar 201 AAC and severe AAC	<ul><li>200 than in their counterparts and showed dif</li><li>201 AAC and severe AAC was significantly h</li></ul>	<ul> <li>than in their counterparts and showed differences among r</li> <li>AAC and severe AAC was significantly higher in participar</li> </ul>	<ul> <li>than in their counterparts and showed differences among races. The prevale</li> <li>AAC and severe AAC was significantly higher in participants with periodont</li> </ul>	than in their counterparts and showed differences among races. The prevalence of mild to m AAC and severe AAC was significantly higher in participants with periodontitis than in those v

			(11 /0/)		
Age, year	$54.96 \pm 0.32$	$53.84 \pm 0.47$	57.13±0.52	$55.78 \pm 0.73$	0.001
Gender					< 0.001
Male	49.54 (42.66-56.42)	44.26 (40.95-47.57)	56.17 (52.43-59.91)	69.60 (62.25-76.96)	
Female	50.46 (44.32,56.60)	55.74 (52.43-59.05)	43.83 (40.09-47.57)	30.40 (23.04-37.75)	
Race					< 0.001
Mexican American	7.98 (4.63-11.32)	5.51 (2.88-8.15)	12.60 (6.75-18.46)	10.53 (4.02-17.05)	
Non-Hispanic Black	10.53 (8.69-12.36)	7.38 (5.67-9.09)	14.16 (9.15-19.17)	23.88 (15.54-32.23)	
Non-Hispanic White	68.14 (54.20-82.08)	74.71 (69.73-79.70)	57.60 (46.77-68.43)	53.28 (42.62-63.94)	
Other Hispanic	5.22 ( 3.48- 6.95)	4.38 (2.56-6.20)	6.79 (4.13-9.44)	6.09 (2.77-9.41)	
Other race or multi-racial	8.14 ( 6.55- 9.74)	8.02 (6.44-9.60)	8.85 (6.07-11.63)	6.21 (4.11-8.31)	
Education					< 0.001
Less than hight school	14.88 (12.36-17.39)	9.09 ( 6.59-11.59)	22.21 (17.08-27.35)	36.60 (27.56-45.64)	
Hight school	20.80 (17.18-24.43)	16.38 (13.54-19.21)	27.28 (22.81-31.75)	33.56 (26.94-40.19)	
Above hight school	64.32 (52.71-75.93)	74.54 (70.84-78.23)	50.51 (44.66-56.35)	29.84 (20.31-39.37)	
Poverty-income ratio					< 0.001
< 1.3	16.84 (12.82-20.86)	10.14 (7.11-13.16)	27.38 (21.64-33.13)	32.91 (20.83-44.99)	
1.3-3.5	34.58 (30.67-38.50)	29.18 (25.57-32.80)	43.20 (38.79-47.62)	46.98 (36.21-57.75)	
> 3.5	48.58 (38.30-58.85)	60.68 (55.49-65.87)	29.41 (23.79-35.03)	20.11 (10.19-30.04)	
Insurance coverage	84.99 (72.54-97.45)	91.46 (88.41-94.50)	76.37 (72.89-79.85)	62.68 (55.51-69.85)	< 0.001
Body mass index (kg/m <sup>2</sup> )					0.053
< 30	64.10 (54.77-73.44)	66.54 (63.36-69.72)	59.50 (53.18-65.82)	61.67 (53.95-69.39)	
$\geq$ 30	35.90 (31.24-40.56)	33.46 (30.28-36.64)	40.50 (34.18-46.82)	38.33 (30.61-46.05)	
Smoking status					< 0.001
Now	16.07 (13.82-18.31)	10.48 (8.12-12.83)	21.91 (18.01-25.81)	42.48 (33.91-51.05)	
Former	25.38 (20.70-30.06)	23.00 (20.09-25.92)	31.13 (25.05-37.20)	22.22 (13.02-31.43)	
Never	58.55 (50.16-66.94)	66.52 (62.55-70.48)	46.96 (42.06-51.87)	35.30 (25.73-44.86)	
Alcohol consumption statu	S				0.004
Never	11.48 (8.45-14.51)	11.22 (7.14-15.29)	12.77 (10.23-15.30)	8.23 ( 4.19-12.27)	
Former	14.23 (11.41-17.06)	11.54 (9.13-13.95)	18.94 (15.82-22.05)	18.63 (12.99-24.26)	
Mild	40.28 (33.73-46.83)	43.77 (39.36-48.18)	34.64 (29.89-39.39)	32.56 (24.85-40.26)	
Moderate	18.10 (14.08-22.11)	18.98 (16.05-21.92)	16.60 (11.73-21.47)	16.44 ( 9.60-23.28)	
Heavy	15.91 (13.83-18.00)	14.49 (12.30-16.68)	17.06 (13.06-21.06)	24.15 (16.68-31.61)	
Cardiovascular diseases	7.43 ( 5.89-8.97)	5.95 (4.53-7.38)	10.68 (7.93-13.43)	6.88 (3.11-10.65)	0.004
Hypertension	56.64 (50.33-62.94)	52.31 (48.43-56.19)	63.24 (59.08-67.39)	67.92 (61.80-74.05)	< 0.001
Diabetes	14.06 (12.22-15.91)	10.83 (8.78-12.87)	21.13 (18.83-23.43)	13.04 (7.94-18.15)	< 0.001
Chronic kidney disease	14.66 (12.77-16.55)	12.21 (10.24-14.19)	19.73 (17.14-22.31)	15.13 (10.15-20.11)	< 0.001

Page	12	of	34
------	----	----	----

AAC-8 score					0.
< 3	94.86 (83.16-100.00)	96.68 (95.23-98.13)	91.78 (89.31-94.25)	91.51 (86.26-96.76)	
$\geq$ 3	5.14 ( 3.60-6.68)	3.32 (1.87-4.77)	8.22 (5.75-10.69)	8.49 (3.24-13.74)	
AAC-24 score					< 0
0	75.67 (64.85-86.49)	77.77 (74.00-81.53)	73.24(67.18-79.30)	66.81(59.03-74.58)	
1-6	19.55 (15.84-23.26)	19.38 (15.83-22.93)	18.75(14.07-23.43)	24.65(17.37-31.93)	
> 6	4.78 (3.66-5.90)	2.85 (1.95-3.76)	8.01(5.59-10.42)	8.54(4.04-13.04)	
Laboratory measurements					
Albumin (g/dL)	$4.27 \pm 0.01$	$4.30 \pm 0.01$	$4.21 \pm 0.02$	$4.20 \pm 0.02$	< 0
Serum calcium (mg/dL)	$9.45 \pm 0.01$	$9.45 \pm 0.01$	$9.43 \pm 0.02$	$9.45 \pm 0.03$	0.4
Serum phosphorus (mg/dL)	$3.79 \pm 0.02$	$3.81 \pm 0.03$	$3.75 \pm 0.02$	$3.78 \pm 0.04$	0.0
Uric acid (mg/dL)	$5.37 \pm 0.03$	$5.29 \pm 0.03$	$5.53 \pm 0.08$	$5.42 \pm 0.13$	0.0
Total 25-hydroxyvitamin D (nmol/L)	73.44±1.18	76.90±1.44	68.78±1.58	61.71±2.42	< 0
Hemoglobin (g/dL)	$14.19 \pm 0.04$	$14.15 \pm 0.04$	$14.20 \pm 0.08$	$14.42 \pm 0.11$	0.0
Total cholesterol (mg/dL)	196.56±0.99	195.79±1.15	197.98±2.45	197.48±3.31	0.7
High-density lipoprotein cholesterol (mg/dL)	54.67±0.60	56.42±0.73	51.79±0.70	50.99±1.19	< 0
Triglycerides (mg/dL)	$162.83 \pm 3.69$	$152.54 \pm 3.39$	$182.64 \pm 9.60$	$171.49 \pm 13.54$	0.

207 Note: Values indicate the weighted mean ± SD or weighted % (95% confidence interval). P-values are weighted.

208 AAC, abdominal aortic calcification.

Table 2 shows the relationships between periodontitis and the AAC-8 score and AAC-24 score in the linear regression analysis. In Model 1, which was adjusted for age, sex, and race, severe periodontitis showed a significant positive correlation with the AAC-8 ( $\beta$ : 0.29; 95% CI 0.08, 0.50) and AAC-24 ( $\beta$ : 0.80; 95% CI 0.25, 1.34) scores compared with no periodontitis. However, the association disappeared in the subsequent models adjusted for additional covariates. In addition, no correlation was found between mild-moderate periodontitis and the AAC-8 score or AAC-24 score.

TABLE 2 Weighted linear regression coefficients ( $\beta$ ) and 95% confidence intervals for periodontal status and AAC score : The United States, 2013 to 2014

	Case/participants	Model 1 β (95% CI), P- value	Model 2 β (95% CI), P- value	Model 3 β (95% CI), P- value
AAC-8 score				
No periodontitis	1142/2149	Reference	Reference	Reference
Mild-moderate periodontitis	787/2149	0.11(-0.05,0.28) P=0.149	0.03(-0.11,0.17) P=0.643	0.02(-0.12,0.17) P=0.740
Severe periodontitis	220/2149	0.29( 0.08,0.50) P=0.015	0.17(-0.07,0.41) P=0.159	0.17(-0.08,0.41) P=0.173
AAC-24 score				
No periodontitis	1142/2149	Reference	Reference	Reference

Mild-moderate periodontitis	787/2149	0.34(-0.10,0.78) P=0.110	0.15(-0.22,0.52) P=0.393	0.14(-0.26,0.54) P=0.472
Severe periodontitis	220/2149	0.80( 0.25,1.34) P=0.011	0.57(-0.01,1.14) P=0.052	0.58(-0.02,1.17) P=0.056

Note: Model 1 was adjusted for age, sex, and race; Model 2 was adjusted for the parameters in Model 1 plus insurance, education level, smoking status, alcohol consumption status, PIR, BMI, diabetes, hypertension, CVD and CKD; and Model 3 was adjusted for the parameters in Model 2 plus albumin, serum calcium, serum phosphorus, uric acid, total 25-hydroxyvitamin D, hemoglobin, TC, HDL-C, and TGs. AAC: abdominal aortic calcification. 

15 16	221	Table 3 presents the association between periodontitis and AAC based on the multivariate logistic
17 18 19	222	regression analysis. In fully adjusted Model 3, severe periodontitis was positively associated with AAC
20 21	223	in the high-AAC risk group (AAC-8 score $\geq$ 3 points) (OR: 2.53; 95% CI 1.04, 6.17) compared with
22 23	224	the low-AAC risk group (AAC-8 score < 3 points). The degree of periodontitis and AAC as defined
24 25 26	225	by the more refined AAC-24 score were further analyzed. Mild-moderate and severe periodontitis were
20 27 28	226	associated with an increased prevalence of severe AAC (OR: 2.25; 95% CI 1.24, 4.06 and OR: 3.60;
29 30	227	95% CI 1.48, 8.78) relative to participants without AAC. Furthermore, this association remained when
31 32	228	participants with mild-moderate AAC were replaced with a reference population; mild-moderate and
33 34 35	229	severe periodontitis were associated with severe AAC (OR: 2.28; 95% CI 1.28, 4.06 and OR: 2.93;
36 37	230	95% CI 1.28, 6.69). In addition, no correlation was found between periodontitis and mild-moderate
38 39	231	AAC.

TABLE 3 Weighted multiple logistic regression coefficients (ORs) and 95% confidence intervals for the association between periodontal status with AAC group: The United States, 2013 to 2014

	Case/participant	Model 1	Model 2	Model 3
	S	OR (95% CI), P- value	OR (95% CI), P- value	OR (95% CI), P- value
AAC-8 score $\geq$ 3 points versus	AAC-8 score < 3 p	ooints		
No periodontitis	46/1142	Reference	Reference	Reference
Mild-moderate periodontitis	66/787	2.07(1.01,4.22) P=0.047	1.79(0.95,3.38) P=0.069	1.84(1.00,3.40) P=0.051
Severe periodontitis	19/220	3.20(1.22,8.40) P=0.025	2.53(1.05,6.11) P=0.040	2.53(1.04,6.17) P=0.043
Mild-moderate AAC versus no	AAC			
No periodontitis	224/1102	Reference	Reference	Reference
Mild-moderate periodontitis	144/723	0.89(0.58,1.38) P=0.561	0.76(0.53,1.08) P=0.113	0.72(0.51,1.02) P=0.061

Severe periodontitis	50/200	1.46(0.79,2.68) P=0.185	1.05(0.52,2.10) P=0.886	0.96(0.48,1.93 P=0.914
Severe AAC versus no AAC				
No periodontitis	40/918	Reference	Reference	Reference
Mild-moderate periodontitis	64/643	2.57(1.35, 4.89) P=0.010	2.19(1.23,3.89) P=0.011	2.25(1.24,4.06 P=0.011
Severe periodontitis	20/170	6.13(2.55,14.72) P=0.002	3.62(1.63,8.06) P=0.004	3.60(1.48,8.78 P=0.008
Severe AAC versus mild-moder	ate AAC			
No periodontitis	40/264	Reference	Reference	Reference
Mild-moderate periodontitis	64/208	2.59(1.49,4.52) P=0.005	2.20(1.27,3.80) P=0.008	2.28(1.28, 4.06 P=0.008
Severe periodontitis	20/70	3.16(1.21,8.22) P=0.025	2.89(1.27,6.60) P=0.015	2.93(1.28, 6.69 P=0.014

Note: Model 1 was adjusted for age, sex, and race; Model 2 was adjusted for the parameters in Model 1 plus insurance, education level, smoking status, alcohol consumption status, PIR, BMI, diabetes, hypertension, CVD and CKD; and Model 3 was adjusted for the parameters in Model 2 plus albumin, serum calcium, serum phosphorus, uric acid, total 25-hydroxyvitamin D, hemoglobin, TC, HDL-C, and TGs. No AAC, mild–moderate AAC and severe AAC were defined by AAC-24 score. AAC: abdominal aortic calcification.

27		
28	239	In the subgroup analysis (Table 4), we investigated the association between periodontitis and
29		
30	240	severe AAC based on an AAC-8 score $\geq$ 3. We found that the likelihood ratio test for multiplicative
31		
32	241	internations was not statistically significant for any CUD hypertansian dishetes on CVD offer
33	241	interactions was not statistically significant for age, sex, CVD, hypertension, diabetes, or CKD after
34		
35	242	adjustment for potential confounders (P interaction $> 0.05$ ). Thus, we did not find any substantial
36		
37	243	evidence to demonstrate systematic differences in associations between different subpopulations in the
38	213	e vidence to demonstrate systematic anterences in associations out their anterent sucpopulations in the
39	244	nonvilation indicating that any main nonvita man stable
40	244	population, indicating that our main results were stable.

245TABLE 4 Subgroup analysis for the association between periodontal status and risk of severe AAC (AAC-8 score246 $\geq$  3 points).

		Periodontal status OR (95% CI), P- value		
	No periodontitis	Mild–moderate periodontitis	Severe periodontitis	P for interaction
Age				0.212
≥60y	Reference	1.90(0.88,4.11) P=0.096	5.66(1.15,27.92) P=0.035	
<60y	Reference	3.44(0.83,14.15) P=0.083	1.58(0.24,10.43) P=0.611	

Gender				0.207
Male	Reference	1.90(0.55,6.56) P=0.285	4.40(1.09,17.85) P=0.039	
Female	Reference	2.37(1.42,3.93) P=0.003	0.92(0.29,2.94) P=0.876	
Cardiovascular diseases				0.381
Yes	Reference	1.61(0.31,8.35) P=0.548	NA*	
No	Reference	1.95(1.02,3.73) P=0.044	2.14(0.86,5.35) P=0.096	
Diabetes				0.837
Yes	Reference	4.00(1.49,10.69) P=0.009	9.64(1.45,64.16)* P=0.022	
No	Reference	1.51(0.67,3.40) P=0.293	2.21(0.76,6.44) P=0.136	
Hypertension				0.085
Yes	Reference	1.81(0.88, 3.74) P=0.099	3.39(1.35, 8.56) P=0.013	
No	Reference	3.27(1.08, 9.91) P=0.037	0.73(0.08, 6.72) P=0.767	
Chronic kidney disease				0.50
Yes	Reference	2.20(1.15, 4.21) P=0.021	1.57(0.22, 11.17) P=0.630	
No	Reference	1.81(0.79, 4.12) P=0.147	2.98(1.21, 7.34) P=0.020	

Note: All presented covariates were adjusted (as Model 3) except the corresponding stratification variable. \*Wide CI
and no production OR are due to the small sample size for this comparison.

In the primary study, we imputed missing covariates (the proportions of all missing variables were less than 5.00% except for the PIR, at 8.19%) using the MissForest package. The random forest analysis had a seed number of 500 and completed data imputation after eight iterations. Model performance indicators normalized root mean squared error computed (NRMSE) was 0.578 and proportion of falsely classified (PFC) was 0.336. In the sensitivity analysis, we excluded participants with missing covariates, and we included 1,818 individuals with complete data in the subsequent analyses. The baseline distribution of participant characteristics did not differ significantly from that in the previously included population, but it was worth mentioning that the prevalence of severe AAC with severe periodontitis have decreased by approximately 1% (Supplementary Material Table 2). Further logistic regression analysis showed, our result regarding the association of periodontitis and AAC differed from that in the primary analysis. In Model 3, only mild-moderate periodontitis was associated with an increased risk of severe AAC (OR: 1.89; 95% CI 1.01, 3.56), and the remaining associations were

BMJ Open: first published as 10.1136/bmjopen-2022-068931 on 15 March 2023. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright

attenuated or had disappeared (Supplementary Material Table 3). When we decoupled mild-moderate periodontitis and excluded participants with mild periodontitis, the results of the sensitivity analysis were similar to those of the main analysis (Supplementary Material Table 4). It is worth mentioning that mild-moderate periodontitis was associated with a reduced prevalence of mild to moderate AAC in participants without CVD, and the association of severe periodontitis with AAC in the high-AAC risk group (AAC-8 scores  $\geq$  3 points) disappeared (Supplementary Material Table 5).

4. Discussion

To our knowledge, this is the first population-based cross-sectional epidemiological study to explore the link between periodontitis and AAC in a nationally representative sample of U.S. adults (40 years and older). Our study fully considered socioeconomic status, behavioral factors and medical history of the participants and controlled for a wide range of confounders. Severe periodontitis was positively associated with severe AAC, defined by either the AAC-8 score or AAC-24 score. A positive association between mild to moderate periodontitis and severe AAC was found only when AAC was classified by the AAC-24 score. In the subgroups stratified by age; sex; and CVD, hypertension, diabetes, and CKD status, this association and the main results were generally consistent; the only difference was associated with the different severities of periodontitis, which differed in their associations with severe AAC in the stratified population. Linear regression evaluation of the AAC-8 score and AAC-24 score as dependent variables and the different severities of periodontitis as independent variables showed no linear correlation. In the sensitivity analysis, the association remained significant after excluding participants with mild periodontitis and CVD. However, the association was no longer significant after excluding participants with missing covariates.

To date, some epidemiological studies have suggested a close relationship between periodontitis
and vascular calcification or CVD. A consensus report on periodontitis and CVD states that

Page 17 of 34

#### BMJ Open

periodontitis is broadly associated with CVD and that the link is bidirectional; CVD drives the progression of periodontitis and vice versa<sup>39</sup>. NHANES-based cross-sectional studies have shown an association between periodontitis severity and cardiovascular risk<sup>4</sup>, as demonstrated by the results of a 13-year cohort study, and further studies suggest that periodontitis may be an independent risk factor for  $CVD^{40}$ . Oindrila Paul et al. reviewed the pathophysiology of periodontitis and showed that inflammation associated with periodontitis may be the main mechanism affecting CVD and could be facilitated by common risk factors<sup>41</sup>. Vascular calcification has been shown to involve soft tissue calcification also caused by chronic inflammatory stimuli<sup>19</sup> and is closely related to the prevalence and prognosis of CVD. This may suggest that the association between periodontitis and CVD may depend on the severity of vascular calcification. The results of a cross-sectional Japanese population-based study suggest that measuring alveolar bone loss on panoramic radiographs may be an effective method to identify an increased risk of carotid artery calcification<sup>14</sup>. Imaging studies using cone-beam computed tomography have further confirmed that the development of periodontitis may cause calcification involving the intracranial carotid arteries<sup>16</sup>. The results from a meta-analysis that included 12 studies also revealed a significant relationship between periodontitis and carotid artery calcification<sup>15</sup>. Similar to our findings, a cohort study in Chinese populations suggested that periodontitis was also positively associated with aortic calcification, and this association was more pronounced in men and in participants younger than 65 years<sup>13</sup>. 

The exact mechanism of the link between periodontitis and AAC remains unclear and needs to be further explored. Existing mainstream views suggest that *Porphyromonas gingivalis* (*P. gingivalis*) infection and chronic inflammation are important bridges between periodontitis and vascular calcification<sup>19, 41-42</sup>. Recent studies have shown that periodontal pathogens can be detected in the blood of patients with coronary heart disease, and it is hypothesized that periodontal pathogens can spread through the blood to other parts of the body, where they may enhance inflammatory processes, leading 

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

to the development or aggravation of atherosclerosis<sup>43</sup>. Evidence from in vitro cell culture studies suggests that *P. gingivalis* infection accelerates phosphate-induced calcification of vascular smooth muscle cells<sup>22</sup> and that *P. gingivalis* lipopolysaccharide increases alkaline phosphatase activity and upregulates the expression of genes involved in calcification to stimulate calcification<sup>44</sup>. In addition, it has been shown that P. gingivalis invasiveness is enhanced after high-glucose treatment, and vascular calcification can be initiated by stimulating autocrine regulation of bone morphogenetic protein 4 in aortic smooth muscle cells<sup>21</sup>. P. gingivalis infection elicits an inflammatory response in the host, which is in line with the definition of periodontitis as a chronic inflammatory disease. A meta-analysis suggested that the diagnosis of chronic aggressive periodontitis was consistently associated with higher C-reactive protein and high-sensitivity C-reactive protein levels, and treatment reduced serum C-reactive protein levels<sup>45</sup>. In addition, studies have observed an association between periodontitis and systemic inflammation, which increases with the severity of periodontal disease<sup>46</sup>. Notably, there are studies revealing other possible mechanisms involved in the link between periodontitis and vascular calcification, including the activation of osteoprotegerin/receptor activator of nuclear factor-kB ligand and endoplasmic reticulum stress-induced apoptosis<sup>23-24</sup>. 

Our study has several important strengths. Our findings were derived from a large nationwide random sample survey and can be generalized to the adult noninstitutionalized population in the U.S. Periodontitis and AAC were defined based on objective clinical data collected by calibrated professionals. In addition, this study addressed a number of known potential confounders, and sample weights were applied in each analysis following the NHANES guidelines to account for the complex survey design. However, several limitations of this study warrant attention. Given the cross-sectional design of the NHANES, it is difficult for us to determine causality, and further large-scale prospective studies are needed. In addition, we cannot exclude the possibility of residual confounding by other confounding factors related to oral health, which could have influenced the observed results. It is worth 

#### **BMJ** Open

noting that only a small proportion of patients with severe periodontitis in our study had severe AAC; perhaps because of this, the results of the sensitivity analysis excluding patients with missing covariates were not robust. This also suggests that the conclusions of this study should be interpreted with caution. An explanation for this phenomenon is the possibility of selection  $bias^{47}$ . In addition, tooth loss is not considered in the CDC/AAP case definition of periodontitis; therefore, the prevalence of the disease may be underestimated<sup>30</sup>. Because of the sample size, we were not able to include the new periodontal profile class (PPC) system to precisely classify periodontal disease because this classification method classifies periodontitis into seven categories: PPC-A to PPC-G<sup>48</sup>. 5. Conclusion Our study suggests that periodontitis is associated with an increased risk of severe AAC in the U.S. population aged 40 years and older. The associations investigated in this study are credible due to their cross-sectional nature, but these findings require further large-scale prospective studies to 4.64 confirm. Acknowledgements The authors gratefully acknowledge the financial supports by the the Construction of key laboratories in Xinjiang Uygur Autonomous Region (Grant No. 2019D04017) and Tianshan Cedar Program (Grant No. 2020XS13). Furthermore, We thank all members of the NHANES teams for surveys and data collection throughout the United States. **Contributors** KK, AnA and AiA participated in the design of the study, analysis of the data and drafted the manuscript or revised it for important content. RR collected and organized data. XM and Y-TM 

1

2 3	353	contributed to the conception and design of the manuscript as well as reviewing critical modifications
4 5 6	354	for important intellectual content.
7 8 9 10	355	Funding
11 12	356	This study was supported by the Construction of key laboratories in Xinjiang Uygur Autonomous
13 14 15	357	Region (Grant No. 2019D04017) and Tianshan Cedar Program (Grant No. 2020XS13).
16 17 18 19	358	Competing interests
20 21 22 23	359	None declared.
23 24 25 26	360	Patient consent for publication
27 28	361	Not applicable.
29 30 31	362	Ethics approval
32 33 34	363	The present study complied with the term of the Declaration of Helsinki and was approved by the
35 36	364	NCHS Research Ethics Review Committee (NCHS IRB/ERB Protocol Number: Continuation of
37 38	365	Protocol #2011-17).
39 40 41 42	366	Data availability statement
43 44 45	367	Data may be obtained from a third party and are not publicly available. Data described in the
46 47	368	article are publicly and freely available without restriction at
48 49 50	369	https://www.cdc.gov/nchs/nhanes/index.htm
51 52 53 54 55 56	370	References
57 58		
59		10

Page 21 of 34

### BMJ Open

national burden of tudy 2019. <i>J Clin</i>	BMJ Open: first published as 10.1136/bmjopen-2022-068931 on 15 March 2023. Downloaded from http://bm
the United States:	olished as 10.113
ciates with risk of	3/bmjopen-2022-C
ween Periodontal 163-168.	68931 on 15 Mar
ol, complications,	ch 2023. Downl
ntitis and chronic	oaded from http:/
ntitis, Edentulism, 100:37-49.	<u> </u>
ontitis: the Centers et. J Periodontol.	√ on April 20, 20;
plaques evolution:	pen.bmj.com/ on April 20, 2024 by guest. Protected by copyright
	rright.

1		
2 3	371	1. Chen MX, Zhong YJ, Dong QQ, Wong HM, Wen YF. Global, regional, and national burden o
4 5	372	severe periodontitis, 1990-2019: An analysis of the Global Burden of Disease Study 2019. J Clin
6 7 8	373	Periodontol. 2021;48:1165-1188.
9 10 11	374	2. Eke PI, Dye BA, Wei L, et al. Update on Prevalence of Periodontitis in Adults in the United States
12 13 14	375	NHANES 2009 to 2012. J Periodontol. 2015;86:611-622.
15 16 17	376	3. Van Dyke TE, Kholy KE, Ishai A, et al. Inflammation of the periodontium associates with risk o
18 19	377	future cardiovascular events. J Periodontol. 2021;92:348-358.
20 21 22	378	4. Sumayin Ngamdu K, Mallawaarachchi I, Dunipace EA, et al. Association Between Periodonta
23 24 25	379	Disease and Cardiovascular Disease (from the NHANES). <i>Am J Cardiol</i> . 2022;178:163-168.
26 27 28	380	5. Genco RJ, Graziani F, Hasturk H. Effects of periodontal disease on glycemic control, complications
29 30 31	381	and incidence of diabetes mellitus. Periodontol 2000. 2020;83:59-65.
32 33	382	6. Parsegian K, Randall D, Curtis M, Ioannidou E. Association between periodontitis and chronic
34 35 36	383	kidney disease. Periodontol 2000. 2022;89:114-124.
37 38 39	384	7. Romandini M, Baima G, Antonoglou G, Bueno J, Figuero E, Sanz M. Periodontitis, Edentulism
40 41 42	385	and Risk of Mortality: A Systematic Review with Meta-analyses. J Dent Res. 2021;100:37-49.
43 44	386	8. Eke PI, Thornton-Evans G, Dye B, Genco R. Advances in surveillance of periodontitis: the Center
45 46	387	for Disease Control and Prevention periodontal disease surveillance project. J Periodontal
47 48 49 50	388	2012;83:1337-1342.
51 52	389	9. Fiz F, Piccardo A, Morbelli S, et al. Longitudinal analysis of atherosclerotic plaques evolution
53 54 55 56 57	390	an <sup>18</sup> F-NaF PET/CT study. <i>J Nucl Cardiol</i> . 2022;29:1713-1723.
58 59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
00		

# Page 22 of 34

# BMJ Open

2 3	391	10. Wilson PW, Kauppila LI, O'Donnell CJ, et al. Abdominal aortic calcific deposits are an important
4 5 6	392	predictor of vascular morbidity and mortality. Circulation. 2001;103:1529-1534.
7 8 9	393	11. Górriz JL, Molina P, Cerverón MJ, et al. Vascular calcification in patients with nondialysis CKD
10 11 12	394	over 3 years. Clin J Am Soc Nephrol. 2015;10:654-666.
13 14 15	395	12. Bendix EF, Johansen E, Ringgaard T, Wolder M, Starup-Linde J. Diabetes and Abdominal Aortic
16 17 18	396	Calcification-a Systematic Review. Curr Osteoporos Rep. 2018;16:42-57.
19 20	397	13. Yu YL, Ma JR, Li SN, et al. Association between Periodontitis and Aortic Calcification: A Cohort
21 22 23	398	Study. Angiology. 2022;33197221094713.
24 25	399	14. Dewake N, Ishioka Y, Uchida K, et al. Association between Carotid Artery Calcification and
26 27	400	Periodontal Disease Progression in Japanese Men and Women: A Cross-Sectional Study. J Clin Med.
28 29 30 31	401	2020;9:3365.
32 33	402	15 Wang W. Vang Z. Wang V. Cas H. Wang V. Zhang O. Association between Deviadentitis and
34 35	402	15. Wang W, Yang Z, Wang Y, Gao H, Wang Y, Zhang Q. Association between Periodontitis and
36 37	403	Carotid Artery Calcification: A Systematic Review and Meta-Analysis. Biomed Res Int.
38 39	404	2021;2021:3278351.
40 41 42	405	16. AlSakr A, Blanchard S, Wong P, Thyvalikakath T, Hamada Y. Association between intracranial
43 44	406	carotid artery calcifications and periodontitis: A cone-beam computed tomography study. $J$
45 46 47	407	Periodontol. 2021;92:1402-1409.
48 49 50	408	17. Nakib SA, Pankow JS, Beck JD, et al. Periodontitis and coronary artery calcification: the
50 51 52 53	409	Atherosclerosis Risk in Communities (ARIC) study. J Periodontol. 2004;75:505-510.
54 55	410	18. Hujoel PP, Drangsholt M, Spiekerman C, DeRouen TA. Periodontal disease and coronary heart
56 57 58	411	disease risk. JAMA. 2000;284:1406-1410.
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 21

1 2	412	19. Li JJ, Zhu CG, Yu B, Liu YX, Yu MY. The role of inflammation in coronary artery
3 4 5	413	calcification. Ageing Res Rev. 2007;6:263-270.
6 7 8	414	20. Li H, Pan K, Meng Y, et al. Mutual promotions between periodontitis and vascular calcification by
9 10 11	415	rat animal model. J Periodontal Res. 2020;55:810-820.
12 13 14	416	21. Chen TC, Lin CT, Chien SJ, Chang SF, Chen CN. Regulation of calcification in human aortic
15 16	417	smooth muscle cells infected with high-glucose-treated Porphyromonas gingivalis. J Cell Physiol.
17 18 19	418	2018;233:4759-4769.
20 21	419	22. Park HJ, Kim Y, Kim MK, et al. Infection of Porphyromonas gingivalis Increases Phosphate-
22 23		
24 25	420	Induced Calcification of Vascular Smooth Muscle Cells. <i>Cells</i> . 2020;9:2694.
26 27 28	421	23. Jiao M, Zhang P, Yu X, et al. Osteoprotegerin/receptor activator of nuclear factor-κB ligand are
29 30	422	involved in periodontitis-promoted vascular calcification. Exp Ther Med. 2022;24:512.
31 32 33	423	24. Song X, Li J, Jiao M, Chen Y, Pan K. Effect of endoplasmic reticulum stress-induced apoptosis in
34 35 36	424	the role of periodontitis on vascular calcification in a rat model. J Mol Histol. 2021;52:1097-1104.
37 38 39	425	25. Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW. New indices to classify
40 41	426	location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up
42 43 44	427	study. Atherosclerosis. 1997;132:245-250.
44 45 46	428	26. Criqui MH, Denenberg JO, McClelland RL, et al. Abdominal aortic calcium, coronary artery
40 47 48		
49	429	calcium, and cardiovascular morbidity and mortality in the Multi-Ethnic Study of
50 51 52	430	Atherosclerosis. Arterioscler Thromb Vasc Biol. 2014;34:1574-1579.
53 54 55	431	27. Johnson CL, Dohrmann SM, Burt VL, Mohadjer LK. National health and nutrition examination
56 57	432	survey: sample design, 2011-2014. Vital Health Stat 2. 2014;162:1-33.
58 59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 22

BMJ Open: first published as 10.1136/bmjopen-2022-068931 on 15 March 2023. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright.

#### **BMJ** Open

3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
50	

60

1

2

28. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet*.
2007;370:1453-1457.

436 29. Dye BA, Afful J, Thornton-Evans G, Iafolla T. Overview and quality assurance for the oral health
437 component of the National Health and Nutrition Examination Survey (NHANES), 2011-2014. *BMC*438 *Oral Health*. 2019;19:95.

439 30. Eke PI, Page RC, Wei L, Thornton-Evans G, Genco RJ. Update of the case definitions for
440 population-based surveillance of periodontitis. *J Periodontol*. 2012;83:1449-1454.

441 31. Schousboe JT, Debold CR. Reliability and accuracy of vertebral fracture assessment with
 442 densitometry compared to radiography in clinical practice. *Osteoporos Int.* 2006;17:281-289.

443 32. Schousboe JT, Lewis JR, Kiel DP. Abdominal aortic calcification on dual-energy X-ray
 <sup>2</sup> 444 absorptiometry: Methods of assessment and clinical significance. *Bone*. 2017;104:91-100.

33. Shah PD, Badner VM, Moss KL. Association between asthma and periodontitis in the US adult
 population: A population-based observational epidemiological study. *J Clin Periodontol*.
 447 2022;49:230-239.

448 34. Chen W, Eisenberg R, Mowrey WB, et al. Association between dietary zinc intake and abdominal
aortic calcification in US adults. *Nephrol Dial Transplant*. 2020;35:1171-1178.

450 35. Whelton PK, Carey RM, Aronow WS, et al.2017
 451 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention,
 452 detection, evaluation, and management of high blood pressure in adults: a report of the American

	Ξ
	ş
	Ξ
	g
	g
	Ð.
	<u> </u>
	2.
	#
	σ
	둙
	≝
	ę
	ดี
	0
	ĝ
	05
	ㅎ
	~
	ニ
	ω
	୍ଦ
	ਵ
	₫.
	2
	8
	Ť
	ŵ
	0
	2
	ï
	ട്
	õ
	ģ
	3
	0
	≚
	<u> </u>
	σı
	<
	a
	2
	÷
	N
	2
	ယ
	<u> </u>
	ð
	2
	<
	5
	<u>n</u> lo
	nloa
	nloade
	nloaded
	nloaded fi
	nloaded fro
	nloaded from
	nloaded from h
	nloaded from http
-	nloaded from http:/
-	nloaded from http://b
_	inloaded from http://bm
-	nloaded from http://bmic
-	inloaded from http://bmjop
-	inloaded from http://bmjope
-	nloaded from http://bmjopen.
-	BMJ Open: first published as 10.1136/bmjopen-2022-068931 on 15 March 2023. Downloaded from http://bmjopen.br
-	nloaded from http://bmjopen.bm
-	nloaded from http://bmjopen.bmj.c
-	nloaded from http://bmjopen.bmj.cov
	nloaded from http://bmjopen.bmj.com
-	nloaded from http://bmjopen.bmj.com/ c
-	nloaded from http://bmjopen.bmj.com/ on
	nloaded from http://bmjopen.bmj.com/ on A
-	nloaded from http://bmjopen.bmj.com/ on Ap
-	nloaded from http://bmjopen.bmj.com/ on April
-	nloaded from http://bmjopen.bmj.com/ on April 2
-	nloaded from http://bmjopen.bmj.com/ on April 20
-	mi.com/ on April 20,
-	nloaded from http://bmjopen.bmj.com/ on April 20, 20
-	mi.com/ on April 20,
-	mi.com/ on April 20, 2024 by quest.
-	mi.com/ on April 20, 2024 by quest.
-	omi.com/ on April 20, 2024 by quest. Prot
-	omi.com/ on April 20, 2024 by quest. Prote
-	omi.com/ on April 20, 2024 by quest. Prot
-	omi.com/ on April 20, 2024 by quest. Prote
-	omi.com/ on April 20, 2024 by quest. Prote
-	omi.com/ on April 20, 2024 by quest. Prote
-	omi.com/ on April 20, 2024 by quest. Prote
-	omi.com/ on April 20, 2024 by quest. Prote
-	omi.com/ on April 20, 2024 by quest. Prote
-	omi.com/ on April 20, 2024 by quest. Prote
-	omi.com/ on April 20, 2024 by quest. Prote

1		
2 3	453	College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am
4 5 6	454	<i>Coll Cardiol</i> . 2018;71:e127–248.
7 8	455	36. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group.
9 10 11	456	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int.
12 13 14	457	2021;100:S1-S276.
15 16	458	37. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration
17 18 19	459	rate. Ann Intern Med. 2009;150:604-612.
20		
21 22	460	38. Stekhoven DJ, Bühlmann P. MissForestnon-parametric missing value imputation for mixed-type
23 24 25	461	data. Bioinformatics. 2012;28:112-118.
26 27 28	462	39. Sanz M, Marco Del Castillo A, Jepsen S, et al. Periodontitis and cardiovascular diseases: Consensus
29 30 31	463	report. J Clin Periodontol. 2020;47:268-288.
32 33	464	40. Tiensripojamarn N, Lertpimonchai A, Tavedhikul K, et al. Periodontitis is associated with
34 35 36	465	cardiovascular diseases: A 13-year study. J Clin Periodontol. 2021;48:348-356.
37 38 39	466	41. Paul O, Arora P, Mayer M, Chatterjee S. Inflammation in Periodontal Disease: Possible Link to
40 41 42	467	Vascular Disease. Front Physiol. 2021;11:609614.
43 44	468	42. Zhang J, Xie M, Huang X, et al. The Effects of Porphyromonas gingivalis on Atherosclerosis-
45 46 47 48	469	Related Cells. Front Immunol. 2021;12:766560.
49 50	470	43. Corredor Z, Suarez-Molina A, Fong C, Cifuentes-C L, Guauque-Olarte S. Presence of periodontal
51 52 53 54 55 56 57	471	pathogenic bacteria in blood of patients with coronary artery disease. <i>Sci Rep.</i> 2022;12:1241.
58		
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 24

# Page 26 of 34

# BMJ Open

1

2

3 4	472	44. Li J, Deng J, Shang S, et al. Effect of Porphyromonas gingivalis lipopolysaccharide on calcification	1
5 6	473	of human umbilical artery smooth muscle cells co-cultured with human periodontal ligament cells. Exp	,
7 8 9	474	<i>Ther Med.</i> 2021;21:655.	
10 11 12	475	45. Machado V, Botelho J, Escalda C, et al. Serum C-Reactive Protein and Periodontitis: A Systematic	)
13 14 15	476	Review and Meta-Analysis. Front Immunol. 2021;12:706432.	
16 17	477	46. Andreu R, Santos-Del-Riego S, Payri F. Serum Inflammatory and Prooxidant Marker Levels in	1
18 19 20	478	Different Periodontal Disease Stages. Healthcare (Basel). 2021;9:1070.	
21 22 23	479	47. Munafò MR, Tilling K, Taylor AE, Evans DM, Davey Smith G. Collider scope: when selection	1
24 25 26	480	bias can substantially influence observed associations. Int J Epidemiol. 2018;47:226-235.	
27 28 29	481	48. Morelli T, Moss KL, Preisser JS, et al. Periodontal profile classes predict periodontal disease	)
30 31 32	482	progression and tooth loss. <i>J Periodontol</i> . 2018;89:148-156.	
33 34	483	Figure legends	
35 36 37	484	Figure 1. Flow chart of eligible National Health and Nutrition Examination Survey (NHANES)	)
38 39	485	participants included in this study.	
40 41			
42 43			
44 45			
46			
47 48			
49			
50			
51 52			
53			
54			
55 56			
57			
58			
59		25	




Figure 1. Flow chart of eligible National Health and Nutrition Examination Survey (NHANES) participants included in this study.

655x679mm (72 x 72 DPI)

# **Supplementary Material**

TABLE 1 The numbers and percentages of missing covariate data

Covariate	Numbers	Percentages (%)
Education	1	0.05
Poverty-income ratio	176	8.19
Body mass index	6	0.28
Smoking status	2	0.09
Alcohol consumption status	97	4.51
Cardiovascular diseases	1	0.05
Chronic kidney disease	52	2.42
Albumin	58	2.70
Serum calcium	72	3.35
Serum phosphorus	59	2.75
Uric acid	60	2.79
Total 25-hydroxyvitamin D	49	2.28
Hemoglobin	38	1.77
Total cholesterol	53	2.47
High-density lipoprotein cholesterol	53	2.47
Triglycerides	60	2.79

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

**TABLE 2** General characteristics of included participants (n = 1,818) according to the periodontal status in the NHANES 2013–2014 (excluded participants with missing covariates).

Characters	Overall (n=1,818)	No Periodontitis (n=977)	Mild-Moderate periodontitisc (n=661)	Severe periodontitis (n=180)	P-val
Age, year	55.19±0.33	$54.01 \pm 0.46$	$57.70 \pm 0.57$	$55.36 \pm 0.69$	< 0.0
Gender					< 0.0
Male	50.34 (43.00-57.67)	45.25 (41.74-48.75)	57.01 (52.84-61.19)	69.00 (60.78-77.22)	
Female	49.66 (43.17-56.16)	54.75 (51.25-58.26)	42.99 (38.81-47.16)	31.00 (22.78-39.22)	
Race	· · · · ·	· · · · · ·	,	,	< 0.0
Mexican American	7.64 (4.29-10.99)	5.37 (2.90-7.83)	12.37 (6.12-18.62)	8.40 (2.34-14.45)	
Non-Hispanic Black	9.81 (8.10-11.53)	7.07 (5.36-8.78)	12.69 (8.36-17.02)	23.04 (14.37-31.72)	
Non-Hispanic White	69.93 (55.21-84.66)	75.53 (70.47-80.58)	60.66 (49.90-71.41)	57.80 (45.71-69.90)	
Other Hispanic	4.87 (3.34-6.40)	4.10 (2.37-5.83)	6.45 (3.97-8.92)	5.27 (1.70-8.84)	
Other race or multi-racial	7.74 ( 6.20- 9.28)	7.94 (6.34- 9.54)	7.83 (4.98-10.68)	5.48 (2.78- 8.18)	
Education	////(0.20//.20)	(0.0 1 ) 10 ()	(100 (100 1000))	0.10 (2.70 0.10)	< 0.0
Less than hight school	13.49 (10.82-16.16)	7.91 (5.25-10.56)	20.34 (14.62-26.06)	36.09 (26.10-46.08)	0.0
Hight school	21.25 (16.88-25.62)	16.12 (12.81-19.42)	29.19 (23.88-34.51)	34.89 (27.67-42.12)	
Above hight school	65.26 (52.75-77.76)	75.98 (71.61-80.34)	50.47 (44.14-56.80)	29.02 (17.31-40.72)	
Poverty-income ratio	03.20 (32.13 11.10)	75.56 (71.61 66.51)	50.17 (11.11 50.00)	29.02 (17.51 10.72)	< 0.0
< 1.3	17.53 (12.79-22.26)	10.69 (7.03-14.35)	28.23 (21.62-34.84)	35.11 (21.93-48.30)	- 0.0
1.3-3.5	32.60 (28.53-36.67)	26.79 (22.77-30.80)	42.48 (37.54-47.42)	44.16 (33.74-54.59)	
> 3.5	49.88 (38.79-60.96)	62.52 (56.61-68.44)	29.29 (23.25-35.33)	20.73 (9.98-31.48)	
<b>Insurance coverage</b>	85.84 (72.59-99.10)	92.31 (89.14-95.48)	77.09 (73.42-80.77)	63.27 (55.48-71.07)	< 0.0
Body mass index (kg/m2)	05.07 (12.59-99.10)	72.51 (07.14-75.40)	(1.0) (13.42-00.77)	03.27 (33.40-71.07)	0.0
< 30	63.56 (53.32-73.81)	66.24 (62.27-70.22)	58.38 (52.44-64.31)	60.96 (51.39-70.54)	0.0
$\geq 30$	36.44 (31.69-41.18)	<b>33.76 (29.78-37.73)</b>	41.62 (35.69-47.56)	39.04 (29.46-48.61)	
	30.44 (31.09-41.18)	55.10 (25.16-51.15)	+1.02 (33.09-47.30)	37.04 (27.40-48.01)	< 0.0
Smoking status Now	16.29 (13.83-18.75)	10 56 ( 7 05 12 16)	22 14 (18 08 26 10)	11 56 (31 80 51 22)	< U.
Former	25.66 (20.34-30.98)	10.56 (7.95-13.16) 22.66 (19.38-25.94)	22.14 (18.08-26.19) 32.94 (26.12-39.75)	44.56 (34.80-54.33) 22.22 (12.52-31.92)	
Never					
	58.05 (49.27-66.83)	66.79 (62.21-71.36)	44.93 (39.88-49.98)	33.22 (22.02-44.41)	0.0
Alcohol consumption status		10 61 (6 27 14 04)	11 70 (0 07 14 22)	7 42 (2 00 11 82)	0.0
Never	10.71 (7.52-13.90)	10.61 (6.27-14.94)	11.70 (9.07-14.33)	7.42 (3.00-11.83)	
Former	14.43 (11.55-17.31)	11.67 (9.23-14.11)	19.33 (16.24-22.41)	19.08 (13.23-24.92)	
Mild	40.15 (32.54-47.76)	43.22 (37.75-48.68)	35.28 (29.93-40.63)	32.53 (24.03-41.03)	
Moderate	18.73 (14.49-22.97)	19.72 (16.57-22.87)	17.18 (11.48-22.88)	16.25 (8.35-24.15)	
Heavy	15.98 (13.25-18.70)	14.79 (11.82-17.77)	16.51 (11.81-21.21)	24.73 (16.17-33.29)	0.0
Cardiovascular diseases	7.82 (6.33-9.32)	6.24 (5.05-7.44)	11.38 (8.50-14.26)	7.24 (2.99-11.48)	0.0
Hypertension	56.45 (49.84-63.06)	52.01 (47.49-56.52)	63.21 (58.69-67.74)	68.69 (63.15-74.24)	< 0.
Diabetes	14.17 (11.92-16.43)	10.97 (9.01-12.93)	21.37 (18.55-24.19)	12.97 (7.27-18.67)	< 0.
Chronic kidney disease	14.93 (12.73-17.13)	12.57 (10.40-14.75)	19.74 (16.90-22.59)	16.15 (10.83-21.47)	< 0.0
AAC-8 score					0.0
< 3	94.75 (82.27-107.22)	96.32 (94.70-97.94)	91.82 (89.49-94.15)	92.69 (88.05-97.32)	
$\geq 3$	5.25 ( 3.65- 6.86)	3.68 (2.06- 5.30)	8.18 (5.85-10.51)	7.31 (2.68-11.95)	
AAC-24 score					0.0
0	75.38 (64.00-86.75)	77.23 (73.37-81.09)	73.27 (67.34-79.21)	67.15 (58.31-76.00)	
1-6	19.79 (15.77-23.82)	19.62 (15.94-23.31)	18.85 (14.06-23.64)	25.48 (17.29-33.67)	
> 6	4.83 ( 3.85- 5.81)	3.15 (2.14-4.16)	7.88 (5.61-10.15)	7.37 (2.91-11.83)	
Laboratory measurements					
Albumin (g/dL)	$4.27 \pm 0.01$	$4.29 \pm 0.02$	$4.22 \pm 0.02$	$4.20 \pm 0.03$	0.0
Serum calcium (mg/dL)	$9.45 \pm 0.01$	$9.45 \pm 0.01$	$9.43 \pm 0.02$	$9.47 \pm 0.03$	0.5
Serum phosphorus (mg/dL)	$3.79 \pm 0.02$	$3.81 \pm 0.03$	$3.74 \pm 0.02$	$3.77 \pm 0.03$	0.0
Uric acid (mg/dL)	$5.37 \pm 0.04$	$5.29 \pm 0.04$	$5.54 \pm 0.10$	$5.45 \pm 0.14$	0.1
Total 25-hydroxyvitamin D (nmol/L)	$73.21 \pm 1.48$	$76.57 \pm 1.85$	$68.88 \pm 1.87$	$60.62 \pm 2.46$	< 0.12
Hemoglobin (g/dL)	$14.21 \pm 0.04$	$14.17 \pm 0.04$	$14.23 \pm 0.09$	$14.44 \pm 0.12$	0.1
Total cholesterol (mg/dL)	$195.97 \pm 1.04$	$195.69 \pm 1.29$	$196.00 \pm 1.97$	$198.53 \pm 3.98$	0.8
High-density lipoprotein cholesterol (mg/dL)	54.62±0.70	56.58±0.85	51.33±0.75	$50.60 \pm 1.43$	< 0.0
Triglycerides (mg/dL)	$160.21 \pm 3.40$	$152.06 \pm 4.25$	$174.33 \pm 4.71$	$175.34 \pm 16.35$	0.0

BMJ Open: first published as 10.1136/bmjopen-2022-068931 on 15 March 2023. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright.

Values indicate the weighted mean ± SD or weighted % (95% confidence interval). P-values are weighted. AAC, abdominal aortic calcification

**TABLE 3** Weighted multiple logistic regression coefficients (ORs) and 95% confidence intervals for the association between periodontal status with AAC group: The United States, 2013 to 2014 (exclude participants with missing covariates)

	Case/participants	Model 1	Model 2	Model 3
	1 1	OR (95% CI), P- value	OR (95% CI), P- value	OR (95% CI), P- value
AAC-8 score ≥ 3 points versus	AAC-8 score < 3 poi	ints		
No periodontitis	44/977	Reference	Reference	Reference
Mild-moderate periodontitis	57/661	1.72(0.84,3.54)	1.53(0.81,2.88)	1.56(0.83,2.92)
wind-moderate periodontitis	577001	p=0.116	p=0.171	p=0.153
Severe periodontitis	15/180	2.44(0.96,6.21)	1.80(0.81,4.00)	1.80(0.77,4.22)
*		p=0.059	p=0.137	p=0.160
Mild-moderate AAC versus no				
No periodontitis	224/939	Reference	Reference	Reference
Mild-moderate periodontitis	144/607	0.87(0.58,1.31)	0.71(0.50,1.02)	0.69(0.49,0.97)
fina moderate periodonities	111/00/	p=0.439	p=0.060	p=0.033
Severe periodontitis	50/164	1.52(0.78,2.96)	1.06(0.49,2.30)	0.99(0.46,2.10)
Severe periodolititis	50/101	p=0.181	p=0.869	p=0.972
Severe AAC versus no AAC				
No periodontitis	38/784	Reference	Reference	Reference
Mild-moderate periodontitis	54/538	2.11(1.10, 4.05)	1.89(1.02, 3.50)	1.89(1.01, 3.56)
tind modelate periodonities	5 11 5 5 6	p=0.030	p=0.044	p=0.048
Severe periodontitis	16/139	5.22(1.85,14.76)	2.81(1.06, 7.42)	2.73(0.92, 8.13)
1		p=0.007	p=0.038	p=0.068
Severe AAC versus mild–mode	erate AAC			
No periodontitis	38/231	Reference	Reference	Reference
Mild-moderate periodontitis	54/177	2.20(1.20,4.04)	1.82(0.98,3.39)	1.87(0.96, 3.66)
wind-moderate periodolititis	JT/1//	p=0.018	p=0.059	p=0.065
Severe periodontitis	16/57	2.41(0.79,7.29)	1.85(0.78,4.38)	1.85(0.75, 4.60)
Severe periodolititis	10/37	p=0.103	p=0.147	p=0.168

Model 1 was adjusted for age, sex, and race; Model 2 was adjusted for the parameters in Model 1 plus insurance, education level, smoking status, alcohol consumption status, PIR, BMI, diabetes, hypertension, CVD and CKD; and Model 3 was adjusted for the parameters in Model 2 plus albumin, serum calcium, serum phosphorus, uric acid, total 25-hydroxyvitamin D, hemoglobin, TC, HDL-C, and TGs. No AAC, mild–moderate AAC and Severe AAC were defined by AAC-24 score. AAC: abdominal aortic calcification.

**TABLE 4** Weighted multiple logistic regression coefficients (ORs) and 95% confidence intervals for the association between periodontal status (exclude participants with mild periodontitis) with AAC group: The United States, 2013 to 2014

	Case/participants	Model 1	Model 2	Model 3
		OR (95% CI), P- value	OR (95% CI), P- value	OR (95% CI), P- value
AAC-8 score ≥ 3 points versus	AAC-8 score < 3 poi	ints		
No periodontitis	34/1142	Reference	Reference	Reference
Moderate periodontitis	53/773	1.94(0.86,4.40) P=0.096	1.68(0.82,3.46) P=0.147	1.73(0.87,3.42) P=0.109
Severe periodontitis	14/220	3.12(1.17,8.36) P=0.029	2.44(1.02,6.00) P=0.046	2.44(1.01,6.05) P=0.048
Mild–moderate AAC versus n	o AAC			
No periodontitis	224/1102	Reference	Reference	Reference
Moderate periodontitis	141/711	0.90(0.57,1.41) P=0.587	0.75(0.52,1.09) P=0.121	0.72(0.50,1.03) P=0.069
Severe periodontitis	50/200	1.46(0.80,2.68) P=0.184	1.05(0.52,2.11) P=0.881	0.96(0.48,1.94) P=0.906
Severe AAC versus no AAC				
No periodontitis	40/918	Reference	Reference	Reference
Moderate periodontitis	62/632	2.37(1.07, 5.22) P=0.036	1.97(0.96,4.06) P=0.063	2.03(1.02,4.03) P=0.044
Severe periodontitis	20/170	6.02(2.44,14.86) P=0.002	3.49(1.53,7.97) P=0.006	3.48(1.42,8.54) P=0.010
Severe AAC versus mild-mod	erate AAC			
No periodontitis	40/264	Reference	Reference	Reference
Moderate periodontitis	62/203	2.47(1.23,4.96) P=0.018	2.10(1.08,4.07) P=0.031	2.17(1.09, 4.32) P=0.030
Severe periodontitis	20/70	3.10(1.15,8.32) P=0.030	2.76(1.16,6.57) P=0.025	2.75(1.14, 6.63) P=0.027

Model 1 was adjusted for age, sex, and race; Model 2 was adjusted for the parameters in Model 1 plus insurance, education level, smoking status, alcohol consumption status, PIR, BMI, diabetes, hypertension, CVD and CKD; and Model 3 was adjusted for the parameters in Model 2 plus albumin, serum calcium, serum phosphorus, uric acid, total 25-hydroxyvitamin D, hemoglobin, TC, HDL-C, and TGs. No AAC, mild–moderate AAC and Severe AAC were defined by AAC-24 score. AAC: abdominal aortic calcification.

BMJ Open: first published as 10.1136/bmjopen-2022-068931 on 15 March 2023. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright

**TABLE 5** Weighted multiple logistic regression coefficients (ORs) and 95% confidence intervals for the association between periodontal status with AAC group: The United States, 2013 to 2014 (exclude participants with cardiovascular diseases)

	Case/participants	Model 1 OR (95% CI), P- value	Model 2 OR (95% CI), P- value	Model 3 OR (95% CI), P- value
AAC-8 score $\geq$ 3 points versus	AAC-8 score < 3 po	× //		
No periodontitis	34/1066	Reference	Reference	Reference
Mild–moderate periodontitis	53/692	2.25(0.98,5.17) P=0.054	1.90(0.95,3.81) P=0.067	1.95(1.02,3.73) P=0.044
Severe periodontitis	14/202	3.27(1.26,8.48) P=0.022	2.18(0.88,5.45) P=0.088	2.14(0.86,5.35) P=0.096
Mild-moderate AAC versus no	AAC			
No periodontitis	208/1038	Reference	Reference	Reference
Mild–moderate periodontitis	118/639	0.83(0.52,1.32) P=0.371	0.68(0.47,0.99) P=0.049	0.65(0.45,0.94) P=0.026
Severe periodontitis	44/187	1.33(0.70,2.51) P=0.330	0.90(0.41,1.95) P=0.774	0.83(0.38,1.81) P=0.618
Severe AAC versus no AAC				
No periodontitis	28/858	Reference	Reference	Reference
Mild–moderate periodontitis	53/574	3.17(1.61, 6.26) P=0.005	2.62(1.44, 4.76) P=0.004	2.71(1.49, 4.93) P=0.003
Severe periodontitis	15/158	6.00(2.47,14.57) P=0.002	3.00(1.31, 6.87) P=0.013	2.89(1.13, 7.40) P=0.029
Severe AAC versus mild-mode	rate AAC			
No periodontitis	28/236	Reference	Reference	Reference
Mild–moderate periodontitis	53/171	3.17(1.73, 5.80) P=0.003	2.99(1.68, 5.32) P=0.001	3.16(1.75, 5.69) P<0.001
Severe periodontitis	15/59	3.79(1.38,10.43) P=0.017	3.82(1.42,10.27) P=0.011	3.75(1.32,10.60) P=0.016

Model 1 was adjusted for age, sex, and race; Model 2 was adjusted for the parameters in Model 1 plus insurance, education level, smoking status, alcohol consumption status, PIR, BMI, diabetes, hypertension and CKD; and Model 3 was adjusted for the parameters in Model 2 plus albumin, serum calcium, serum phosphorus, uric acid, total 25-hydroxyvitamin D, hemoglobin, TC, HDL-C, and TGs. No AAC, mild-moderate AAC and Severe AAC were defined by AAC-24 score. AAC: abdominal aortic calcification.

BMJ Open: first published as 10.1136/bmjopen-2022-068931 on 15 March 2023. Downloaded from http://bmjopen.bmj.com/ on April 20, 2024 by guest. Protected by copyright

3 4

STROBE Statement-	-Checklist of items that	at should be included in reports of <i>cross-sectional studies</i>	/bmjopen-2022-068
	Item No	Recommendation	Page number and Line number
Title and abstract	1 ✓title+abstract	( <i>a</i> ) Indicate the study's design with a commonly used term in the title or the abstract	Page 1-2 9 Line 2-4; 15-36 5
		( <i>b</i> ) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 1-2 Line 2-4; 15-36 →
Introduction			2023
Background/rationale	$2\checkmark$ introduction	Explain the scientific background and rationale for the investigation being reported	Page 3-4 0 Line 47-73
Objectives	$3\checkmark$ introduction	State specific objectives, including any prespecified hypotheses	Page 4 Q Line 74-83
Methods			
Study design	4 ✓ data source	Present key elements of study design early in the paper	Page 5 to the second se
Setting	5 ✓ data source	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 5 9 Line 86-105 9
Participants	6 ✓ data source	( <i>a</i> ) Give the eligibility criteria, and the sources and methods of selection of participants	Page 5
Variables	7 ✓ definitions of periodontitis; abdominal aortic calcification outcomes; covariates	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 5-8 09 Line 106-162 April 20, 2024
Data sources/ measurement	8* ✓ definitions of periodontitis; abdominal aortic calcification outcomes; covariates	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 5-8 Line 106-162 Protected
Bias	9 ✓ statistical analysis	Describe any efforts to address potential sources of bias	Page 8-9 $\checkmark$
Study size	10 ✓ data source;	Explain how the study size was arrived at	Line 163-191 8 Page 5 5

	BMJ Open		DITI Pag
figure 1;		Line 86-105	/bm mjopen- 20222- -06 89331
11 ✓ statistical analysis	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 8-9 Line 163-191	68 93 1 on v
12 ✓ statistical analysis ✓ statistical analysis	<ul> <li>(a) Describe all statistical methods, including those used to control for confounding</li> <li>(b) Describe any methods used to examine subgroups and</li> </ul>	Page 8-9 Line 163-191 Page 8-9	15 March 2023.
<ul><li>✓ statistical analysis </li><li>✓ statistical analysis</li></ul>	(c) Explain how missing data were addressed	Page 8-9 Line 163-191	Downloaded
$\checkmark$ statistical analysis	<ul> <li>(d) If applicable, describe analytical methods taking account of sampling strategy</li> <li>(e) Describe any sensitivity analyses</li> </ul>	Page 8-9 Line 163-191 Page 8-9	ded from http://
13* ✓ data source; figure 1 ✓ data source; figure	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 5 Line 86-105	open.bmj.com/
1;supplementary table1	(b) Give reasons for non-participation at each stage	Page 5 Line 86-105	on April
✓figure 1	(c) Consider use of a flow diagram	-	20,
14* ✓ table 1	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 9-11 Line 196-211	2024 by gu
✓ supplementary table1	(b) Indicate number of participants with missing data for each variable of interest	-	est.
15* ✓ Table 1 to 4	Report numbers of outcome events or summary measures	-	
16 ✓ table 2; table 3; Table 4;	( <i>a</i> ) Give unadjusted estimates and, if applicable, confounder- adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and	-	Protected by copyright.
	analysis 12 $\checkmark$ statistical analysis $\checkmark$ statistical analysis $\checkmark$ statistical analysis $\uparrow$ statistical analysis $\uparrow$ statistical analysis $\uparrow$ supplementary table 1 $\uparrow$ supplementary $\downarrow$	figure 1;       Explain how quantitative variables were handled in the analysis         analysis       Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why         12 ✓ statistical analysis       (a) Describe all statistical methods, including those used to control for confounding         ✓ statistical analysis       (b) Describe any methods used to examine subgroups and interactions         ✓ statistical analysis       (c) Explain how missing data were addressed         ✓ statistical analysis       (d) If applicable, describe analytical methods taking account of sampling strategy         (e) Describe any sensitivity analyses       (e) Describe any sensitivity analyses         13* ✓ data source;       (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility,         ✓ data source;       (a) Report numbers of non-participation at each stage         figure 1       (b) Give reasons for non-participation at each stage         itable1       (c) Consider use of a flow diagram         ital* ✓ table 1       (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders         ✓ supplementary       (b) Indicate number of participants with missing data for each variable of interest         15* ✓ Table 1 to 4       Report numbers of outcome events or summary measures         16 ✓ table 2; table 3;	figure 1;Line 86-10511 $\checkmark$ statistical analysisExplain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and whyPage 8-9 Line 163-191 Page 8-912 $\checkmark$ statistical analysis(a) Describe all statistical methods, including those used to boscribe any methods used to examine subgroups and interactionsPage 8-9 Line 163-191 $\checkmark$ statistical analysis(b) Describe any methods used to examine subgroups and interactionsPage 8-9 Line 163-191 $\checkmark$ statistical analysis(c) Explain how missing data were addressedPage 8-9 Line 163-191 $\checkmark$ statistical analysis(c) Explain how missing data were addressedPage 8-9 Line 163-191 $\checkmark$ statistical analysis(d) If applicable, describe analytical methods taking account of sampling strategyPage 8-9 Line 163-191 $\checkmark$ statistical analysis(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, figure 1Page 5 Line 86-105 $\checkmark$ data source; figure 1(a) Give characteristics of study participants (eg demographic, confoundersPage 5 Line 86-105 $\checkmark$ figure 1(a) Give characteristics of study participants (eg demographic, confoundersPage 9-11 Line 196-211 $\checkmark$ supplementary table1(b) Indicate number of participants with missing data for each variable of interest-15* $\checkmark$ table 1 to 4Report numbers of outcome events or summary measures-16 $\checkmark$ table 2; table 3; (a) Give unadjusted estimates and, if applica

#### BMJ Open

34		BMJ Open		/bmjopen-2022-068931
				n-2022
		why they were included		06
	✓ covariates	(b) Report category boundaries when continuous variables were	Page 7-8	893
		categorized	Line 133-162	- 
		(c) If relevant, consider translating estimates of relative risk	-	<u>ъ</u>
	× this study does	into absolute risk for a meaningful time period		March
	not involve			rch
Other analyses	$17 \checkmark \text{results}$	Report other analyses done-eg analyses of subgroups and	Page 13-15	2023.
		interactions, and sensitivity analyses	Line 242-270	а — <del>П</del>
Discussion				оwr
Key results	$18 \checkmark \text{discussion} - 1^{\text{nd}}$	Summarise key results with reference to study objectives	Page 15	lloaded
	paragraph	<b>b</b>	Line 272-286	de
Limitations	$19 \checkmark discussion - 4^{th}$	Discuss limitations of the study, taking into account sources of	Page 17-18	from
	paragraph	potential bias or imprecision. Discuss both direction and	Line 329-345	
		magnitude of any potential bias		http://bmjopen
Interpretation	$20 \checkmark \text{discussion} - 2^{\text{th}}$ -	Give a cautious overall interpretation of results considering	Page 15-17	- Marine - M
	3 <sup>th</sup> paragraphs	objectives, limitations, multiplicity of analyses, results from	Line 287-328	per
		similar studies, and other relevant evidence		1. br
Generalisability	21 $\checkmark$ discussion – 4 <sup>th</sup>	Discuss the generalisability (external validity) of the study	Page 17-18	ij.com/
		results	Line 329-345	
Other information				
Funding	22 🗸	Give the source of funding and the role of the funders for the	Page 19	April
		present study and, if applicable, for the original study on which	Line 362-363	20,
		the present article is based		2024

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.stopbe-statement.org.

copyright.